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ABSTRACT
Secondary Analysis of Case-Control Studies
in Genomic Contexts. (August 2010)
Jiawei Wei, B.S., Zhejiang University;
M.S., Texas A&M University
Chair of Advisory Committee: Dr. Raymond J. Carroll
This dissertation consists of five independent projects. In each project, a novel
statistical method was developed to address a practical problem encountered in ge-
nomic contexts. For example, we considered testing for constant nonparametric effects
in a general semiparametric regression model in genetic epidemiology; analyzed the
relationship between covariates in the secondary analysis of case-control data; per-
formed model selection in joint modeling of paired functional data; and assessed the
prediction ability of genes in gene expression data generated by the CodeLink System
from GE.
In the first project in Chapter II we considered the problem of testing for constant
nonparametric effects in a general semiparametric regression model when there is the
potential for interaction between the parametrically and nonparametrically modeled
variables. We derived a generalized likelihood ratio test for this hypothesis, showed
how to implement it, and gave evidence that it can improve statistical power when
compared to standard partially linear models.
The second project in Chapter III addressed the issue of score testing for the
independence of X and Y in the second analysis of case-control data. The semipara-
metric efficient approaches can be used to construct semiparametric score tests, but
they suffer from a lack of robustness to the assumed model for Y given X . We showed
how to adjust the semiparametric score test to make its level/Type I error correct
iv
even if the assumed model for Y given X is incorrect, and thus the test is robust.
The third project in Chapter IV took up the issue of estimation of a regression
function when Y given X follows a homoscedastic regression model. We showed how
to estimate the regression parameters in a rare disease case even if the assumed model
for Y given X is incorrect, and thus the estimates are model-robust.
In the fourth project in Chapter V we developed novel AIC and BIC-type meth-
ods for estimating the smoothing parameters in a joint model of paired, hierarchical
sparse functional data, and showed in our numerical work that they are many times
faster than 10-fold crossvalidation while at the same time giving results that are
remarkably close to the crossvalidated estimates.
In the fifth project in Chapter VI we introduced a practical permutation test
that uses cross-validated genetic predictors to determine if the list of genes in ques-
tion has “good” prediction ability. It avoids overfitting by using cross-validation to
derive the genetic predictor and determines if the count of genes that give “good”
prediction could have been obtained by chance. This test was then used to explore
gene expression of colonic tissue and exfoliated colonocytes in the fecal stream to
discover similarities between the two.
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1CHAPTER I
INTRODUCTION
This dissertation consists of five independent projects. In each project, a novel sta-
tistical method was developed to address a practical problem encountered in genomic
contexts. In the first project, we considered the problem of testing for constant
nonparametric effect in a general semiparametric regression model when there is the
potential for interaction between the parametrically and nonparametrically modeled
variables. The work was originally motivated by a unique testing problem in genetic
epidemiology (Chatterjee, et al., 2006) that involved a typical generalized linear model
but with an additional term reminiscent of the Tukey one-degree-of-freedom formu-
lation. In this formulation, there are genetic variables, environmental variables, and
demographic variables. The interest is in testing for main effects of the genetic vari-
ables, while gaining statistical power by allowing for a possible interaction between
genes and the environment. Later work (Maity, et al., 2009) involved the possibil-
ity of modeling the environmental variable nonparametrically, but they focused on
whether there was a parametric main effect for the genetic variables. In this study,
we consider the complementary problem, where the interest is in testing for the main
effect of the nonparametrically modeled environmental variable. We derive a gener-
alized likelihood ratio test for this hypothesis, show how to implement it, and give
evidence that it can improve statistical power when compared to standard partially
linear models. An empirical example involving colorectal adenoma is used to illustrate
the methodology.
The second project addressed the issure of score testing for independence in the
The journal model is Journal of the American Statistical Association.
2secondary analysis of case-control data. Typical case-control studies focus on the
relationship between disease D and covariates (Y,X). In the secondary analysis of
case-control data, it is the relationship between Y and X that is of interest, but the
analysis of this relationship is complicated by the case-control sampling framework,
which is a type of biased sampling. Previous work has assumed a parametric distri-
bution for Y given X and derived semiparametric efficient estimation and inference
without any distributional assumptions about X : of course, the roles of X and Y
can be interchanged. In this study, we take up the issue of score testing for the
independence of X and Y . The semiparametric efficient approaches can be used to
construct semiparametric score tests, but they suffer from a lack of robustness to the
assumed model for Y given X . We take an entirely different and novel approach.
We show how to adjust the semiparametric score test to make its level/Type I error
asymptotically correct in the rare disease case even if the assumed model for Y given
X is incorrect, and thus the test is model robust. Extensions to linear regression with
additional covariates are discussed. Simulations and an empirical example are used
to illustrate the approach.
The third project took up the issue of estimation of a regression function when
Y given X follows a homoscedastic regression model in the secondary analysis of
case-control data. The semiparametric efficient approaches can be used to construct
semiparametric efficient estimates, but they suffer from a lack of robustness to the
assumed model for Y given X . We take an entirely different and novel approach in
the case that the disease is rare. We show how to estimate the regression parameters
in the rare disease case even if the assumed model for Y given X is incorrect, and
thus the estimates are model-robust. Simulations and an empirical example are used
to illustrate the approach.
We developed novel AIC and BIC type methods for estimating smoothing param-
3eters in a joint model of paired, sparse functional data in the fourth project. Utilizing
penalized B-splines, a new approach proposed by Zhou, et al. (2008) jointly models a
pair of sparsely observed functions through functional principal components. In their
approach, a stepwise addition and deletion procedure is employed to decide upon
the number of principal components (PCs) and crossvalidation is used to estimate
penalty parameters. However the choice of the cutoff point in the stepwise addition
and deletion procedure is subjective and the crossvalidation computation is very time
consuming. In this project we propose to select the number of PCs and estimate
the penalty parameters with a modified version of the Akaike information criterion
(AIC) and two modified versions of the Bayesian information criterion (BIC). Our
methods are computationally fast and straightforward to implement. We illustrate
our methods with simulations and the empirical data example used by Zhou, et al.
(2008).
In the fifth project, we introduced a practical permutation test that uses cross-
validated genetic predictors to determine if the list of genes in question has “good”
prediction ability. We call our the cross-validated permutation test. It avoids over-
fitting by using cross-validation to derive the genetic predictor and determines if the
count of genes that give “good” prediction could have been obtained by chance. This
test is then used to explore gene expression of colonic tissue and exfoliated colono-
cytes in the fecal stream to discovery similarities between the two, done at each of
the three stages of colonic tumorigenesis.
4CHAPTER II
TESTING FOR CONSTANT NONPARAMETRIC EFFECTS IN GENERAL
SEMIPARAMETRIC REGRESSION MODELS WITH INTERACTIONS
In this study, we consider the problem of testing for constant nonparametric effect in
a general semiparametric regression model when there is the potential for interaction
between the parametrically and nonparametrically modeled variables. The work was
originally motivated by a unique testing problem in genetic epidemiology (Chatterjee,
et al., 2006) that involved a typical generalized linear model but with an additional
term reminiscent of the Tukey one-degree-of-freedom formulation. In this formula-
tion, there are genetic variables, environmental variables, and demographic variables.
The interest is in testing for main effects of the genetic variables, while gaining statis-
tical power by allowing for a possible interaction between genes and the environment.
Later work (Maity, et al., 2009) involved the possibility of modeling the environmen-
tal variable nonparametrically, but they focused on whether there was a parametric
main effect for the genetic variables. In this study, we consider the complementary
problem, where the interest is in testing for the main effect of the nonparametrically
modeled environmental variable. We derive a generalized likelihood ratio test for this
hypothesis, show how to implement it, and give evidence that it can improve statisti-
cal power when compared to standard partially linear models. An empirical example
involving colorectal adenoma is used to illustrate the methodology.
A. Introduction
We consider the problem of testing for constant nonparametric effects in a general
semiparametric regression model when there is the potential for interaction between
the parametrically and nonparametrically modeled variables. The work was originally
5motivated by a unique testing problem in genetic epidemiology. Chatterjee, et al.
(2006) considered the following logistic regression type problem. Let Y be a binary
response, X a set of covariates that might possibly interact with a scalar covariate
Z, and let S be additional variables not thought to interact with Z. Let H(·) be the
logistic distribution function. Then they propose the model
pr(Y = 1|X,S, Z) = H(κ0 +XTβ0 + STη0 + Zθ0 + γXTβ0Zθ0). (2.1)
In their context, X represented a set of genetic variables such as single nucleotide
polymorphisms (SNP), S were demographic variables and Z was an environmental
effect. Their interest was in testing for a possible genetic main effect, H0 : β0 = 0
versus HA : β0 6= 0. When γ = 0, this is nothing more than an ordinary logistic
regression model, and thus the test is routine. However, Chatterjee, et al. argue that
if there is a possible gene-environment interaction, then capturing it via the Tukey-like
1-degree of freedom term γXTβ0Zθ0 has the potential to increase statistical power
greatly. They document this increase in power both in simulations and in empirical
work.
It is important to see that γ in (2.1) is not identifiable, because under the null
hypothesis, it disappears from the model. Hence, it is not a parameter to be estimated
per se, but is rather a tuning constant. Chatterjee, et al. fix γ along a range of values
L ≤ γ ≤ R, compute the score test T (γ) for each γ, and then take the maximum
value as the final test statistic. They then develop a simulation-based procedure for
computing an overall p-value.
Maity, et al. (2009) generalized models such as (2.1) to allow the effect of the
environmental variable Z to enter nonparametrically. Thus, for an unknown function
6θ0(·), their generalization of (2.1) becomes
pr(Y = 1|X,S, Z) = H {XTβ0 + STη0 + θ0(Z) + γXTβ0θ0(Z)} . (2.2)
They developed a testing procedure in model (2.2) for testing H0 : β0 = 0 versus HA :
β0 6= 0, and demonstrated increased power both via simulations and via empirical
work. As in Chatterjee, et al., Maity, et al. fix γ along a range of values L ≤ γ ≤ R,
compute the profile likelihood score test T (γ) for each γ, and then take the maximum
value as the final test statistic. They also develop a simulation-based procedure for
computing an overall p-value.
Both Chatterjee, et al. (2006) and Maity, et al. (2009) were focused on testing
for the main effect of a gene. However, testing for a main effect of the environmental
variable is also of great interest. In this study, we take up the question of testing
whether Z has any effect in model (2.2), i.e., H0 : θ(z) = constant. Of course,
when we set γ = 0, the result is a standard partially linear logistic model. We will
demonstrate that our testing procedure based on model (2.2) has the potential for
great gains in power, with little loss of power if γ = 0 actually obtains. Similar to
these papers, we will vary γ along a fixed range, form test statistics, maximize, and
then use simulation to form a final p-value. We too will demonstrate the potential
for an increase in power both in simulations and in empirical work.
An outline of this note is as follows. In Section B we will develop the statistical
methodology for more general problems than logistic regression. Section C gives a
simulation study, while Section D describes empirical work. The technical details
justifying the method are described for the logistic case in the Appendix A.
7B. Methodology
1. Basic Framework
Let (X,S) be vectors that do not have an entry 1.0 for an intercept.
Our methodology applies to general loglikelihood functions of the form
L{Y,XTβ0 + STη0 + θ0(Z) + γXTβ0θ0(Z), ζ0} , (2.3)
where β0 and η0 are the main effects, θ0(•) is an unknown function, ζ0 is a nuisance
parameter and γ is the interaction effect that is not to be estimated directly since
it is unidentified when either β0 = 0 or θ0(·) is a constant. All technical details will
be exhibited for the logistic model (2.2), although as we indicate below, the result
holds much more generally. As stated previously, the null hypothesis is H0 : θ0(·) =
constant.
2. Estimation of Model Components
To test H0, we use the concept of a generalized likelihood ratio test (Fan et al., 2001).
To implement the testing procedure, we need to estimate the model components under
the full and null models.
We use a kernel based profile method to estimate the parameters under the full
model. Let K(·) be a symmetric density function and for any bandwidth h, let
Kh(t) = K(t/h)/h. Then the local linear profile method works as follows: for any
given (β, η, ζ) = (β∗, η∗, ζ∗) and γ, we maximize the local loglikelihood
n∑
i=1
Kh(Zi − z0)L
(
Yi, α0 + α1(Zi − z0) +XTi β∗[1 + γ{α0 + α1(Zi − z0), ζ∗}] + STi η∗
)
with respect to α0 and α1, and set θ̂(z0, β
∗, η∗, ζ∗, γ) = α̂0. Then the profile estimates
8of (β, η, ζ) is obtained by maximizing
∑n
i=1L
{
Yi, X
T
i β + S
T
i η + θ̂(Z, β, η, ζ, γ) + γX
T
i βθ̂(Z, β, η, ζ, γ), ζ
}
. (2.4)
Let the resulting estimator be (β̂F , η̂F , ζ̂F ), where it is understood that these estimates
depend on the value of γ chosen.
Estimation under the null model is a purely parametric problem where one com-
putes the MLE in the reduced model under H0. We add an intercept κ so that we
are maximizing
∑n
i=1L
(
Yi, κ+X
T
i β + S
T
i η, ζ
)
.
Let (κ̂R, β̂R, η̂R, ζ̂R) be the resulting null model estimates.
Remark 1 For specific models, the maximization of (2.4) is quite simple and can
be implemented easily. For example, in logistic regression, the steps are as follows.
There is no nuisance parameter ζ . For any given (β, η), define Ui = XTi β + STi η and
Vi = 1 + γXTi β. Then θ̂(z0, β, η, γ) is the estimated intercept ξ0 in the linear logistic
regression model
pr(Yi = 1) = H {Ui + ξ0Vi + ξ1Vi(Zi − z0)}
with the weights Kh(Zi − z0). This procedure is a weighted logistic regression with
no intercept, an offset Ui, and predictors Vi and Vi(Zi − z0), and is hence easily
implemented. Computing (β̂F , η̂F ) is then done by performing maximum likelihood
under the model pr(Yi = 1) = H{XTi β+STi η+θ̂(Z, β, η, γ)+γXTi βθ̂(Z, β, η, γ)} based
on profile method. We used the function optim() in R with initial values estimated
by backfitting.
93. Properties of Profile Estimates of Parameters and Functions
In order to be able to draw upon the work of Fan and Huang (2005) and Fan, et al.
(2001), we require to know the properties of the parameter and function estimates
under the null hypothesis of constant θ0(·).
The properties of profile estimates of parameters and function estimates have
been well-studied in fairly general contexts, see for example Claeskens and Van Kei-
legom (2003), Claeskens and Carroll (2007), Van Keilegom and Carroll (2007) and
Apanasovich, et al. (2009), among many others. Specifically, the parameter estimates
are n1/2-consistent and the function estimates have uniform linear expansions to order
op(n
−1/2). Conditions, summarized in Apanasovich, et al. (2009) and translated to
our context, are as follows. All assumptions are meant to apply to the null hypothe-
sis, since our asymptotic results pertain only to the null hypothesis of constant θ0(·).
This means that there are simplifications to the calculations of Apanasovich, et al.
(2009), who also study misspecified models, a topic not of relevance in this study.
(C.1) The kernel function K is a symmetric, continuously differentiable density func-
tion on [−1, 1] taking on the value zero at the boundaries.
(C.2) The bandwidth is h ∝ n−1/5.
(C.3) The random variables (X,S, Z) have compact support. The design density fZ(·)
of Z is strictly positive and twice continuously differentiable on its support.
(C.4) The parameter space, here denoted by B, is compact. For any (β∗, η∗, ζ∗),
let θ(z0, β
∗, η∗, ζ∗, γ) be the maximizer in v of E[L{Y, v + XTβ∗(1 + γv) +
STη∗, ζ∗}|Z = z0], which is assumed to exist. The function θ(·, β, η, ζ, γ) has 3
continuous derivatives in its arguments. We also assume that the same calcu-
lations done by Claeskens and Carroll (2007) can be applied to our context.
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(C.5) For each γ, and under the null hypothesis, θ(z, β, η, ζ, γ) is constant in z,
(β0, η0, ζ0) is the unique maximizer ofE(L[Y, θ(Z, β, η, ζ, γ)+XTβ{1+γθ(Z, β, η,
ζ, γ)}+STη, ζ ]). In addition, the second total derivative of this function is uni-
formly negative definite in a neighborhood of (β0, η0, ζ0).
(C.6) We can apply the results of Claeskens and Van Keilegom (2003) as needed. In
particular, their assumptions imply that uniformly in z0, for random variables
Ri possessing sufficient moments, then if subscript (1) means first derivative, if
Cn = n
−1∑n
i=1Kh(Zi − z0)(Zi − z0)jRi × {θ(z0) + (Zi − z0)θ(1)(z0)};
Dn = n
−1∑n
i=1Kh(Zi − z0)(Zi − z0)jRi × {θ(Zi)},
then
supz0 |Cn −E(Cn)| = Op[hj{log(n)/(nh)}1/2];
supz0 |Dn − E(Dn)| = Op[hj{log(n)/(nh)}1/2].
Under these assumptions, at the null hypothesis, their work can be easily ex-
tended to show that uniformly on compact sets of γ, (β̂F , η̂F , ζ̂F ) are n
1/2-consistent
estimates of (β0, η0, ζ0).
In addition, at the null hypothesis, we have the following result, also uniform in
compact sets of γ. If the parameter space for (β, η, ζ) is B, the true parameter value
is B0, and if subscripts Lθ(·) and Lθθ(·) denote the first and second derivatives with
respect to θ, respectively, define
Ω(z0,B0) = E(Lθθ[Y, θ(z0, β0, η0, ζ0) +XTβ0{1 + γθ(z0, β0, η0, ζ0)}+ STη0]|Z = z0).
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Then, with θ0(z0) ≡ θ0 at the null hypothesis,
θ̂(z0, β0, η0, ζ0, γ) = θ0 − n−1
∑n
i=1Kh(Zi − z0)Ri + op(n−1/2); (2.5)
Ri = −Lθθ{Yi, θ0 +X
Tβ0(1 + γθ0) + S
Tη0, ζ0}
fZ(z0)Ω(z0,B0)
4. Generalized Likelihood Ratio Test
Given any fixed γ, the generalized likelihood ratio test statistic is given by
Λn(γ) =
∑n
i=1
[
L
{
Yi, X
T
i β̂F + S
T
i η̂F + θ̂(Z, β̂F , η̂F , ζ̂F , γ)
+ γXTi β̂F θ̂(Z, β̂F , η̂F , ζ̂F , γ), ζ̂F
}
− L
{
Yi, κ̂R +X
T
i β̂R + S
T
i η̂R, ζ̂R
}]
.
UnderH0, from Section 3 we have that the parameters are estimated n
1/2-consistently.
As in Fan and Huang (2005), this means that the likelihood ratio statistic behaves
asymptotically as if the parameters are known. As they note, it is easy to show that
the likelihood ratio statistic is Λn(γ) = Λ
∗
n(γ) +Op(1), where
Λ∗n(γ) =
∑n
i=1
[
L
{
Yi, X
T
i β0 + S
T
i η0 + θ̂(Z, β0, η0, ζ0γ) + γX
T
i β0θ̂(Z, β0, η0, ζ0γ), ζ0
}
−L
{
Yi, κ0 +X
T
i β0 + S
T
i η0, ζ0
}]
.
This statistic is easily analyzed because of the expansion (2.5), and indeed that expan-
sion allows us to use almost exactly the proof in Fan, et al. (2001), see also Fan and
Jiang (2005). Useful special cases of this general framework are the partially linear
Gaussian and partially linear logistic regression models. We will show the following
result for the partially linear logistic regression model in Appendix A. However, it
is clear from the proof that an analogous result can be easily established for general
likelihood problems.
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Theorem 1 Assume conditions (C.1)-(C.6). There is a constant rK depending on
the kernel function and a deterministic sequence µn(h) ∝ h−1 →∞ depending on the
bandwidth h such that
rK {Λ∗n(γ)− µn(h)} /{2rKµn(h)}1/2 ⇒ Normal(0, 1). (2.6)
A consequence of Theorem 1 is that because µn(h)→∞,
rK {Λn(γ)− µn(h)} /{2rKµn(h)}1/2 ⇒ Normal(0, 1). (2.7)
Result (2.7) is the so-called Wilks-phenomenon, namely that the semiparametric like-
lihood ratio statistic has a common limiting distribution under the null hypothesis
independent of the problem.
5. Test Statistic and Implementation
While (2.7) holds, it is not very useful in practice for decision making because it
depends upon the bandwidth. This fact motivated Fan and Jiang (2005) to use a
bootstrap-type test. Here we propose a parametric bootstrap-type test to overcome
this problem (see below).
Since the true value of γ is unknown, we follow the idea of Davies (1987), Chat-
terjee, et al. (2006) and Maity, et al. (2009) and propose to use as the test statistic
T ∗n = max
L≤γ≤R
Λn(γ),
where L and R are pre-specified lower and upper bounds for γ. A normalized version
of T ∗n as in (2.7) converges to the maximum of a Gaussian process, see the Appendix
A. However, this is not very useful in terms of setting a critical level due to the
dependence upon the bandwidth. We propose instead a simulation based approach
to compute p-values as follows.
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• Let B be a large number, and for b = 1, ..., B, generate response data Yib from
the null model fits.
• For each of the b = 1, ..., B generated data sets, compute the test statistic T ∗n,b.
• The p-value is then computed as B−1∑Bb=1 I(T ∗n,b > T ∗n ).
C. Simulation Study
We simulated data using the partially linear logistic model
pr(Y |X,Z) = H{XTβ0 + θ(z) + γXTβ0θ(z)},
where H(·) denotes the logistic distribution function. The sample size was n = 1, 200,
X was standard bivariate normal, β0 = (1,−1)T, and Z was uniform on [−2, 2]. We
repeated the simulation 1, 000 times, for true values γtrue = 0, 1, 2. For each simulated
data set, we fit the null model, namely logistic in X , then simulated from this null
model B = 1, 000 times to obtain a p-value. The values of γ used to construct
our test statistic were 11 equally spaced values on the interval [−2, 2]. We used the
Epanechnikov kernel to estimate the function θ(·) and used bandwidth h = σ̂Zn−1/5,
where σ̂Z is the standard deviation of Z. The results were not sensitive to varying h
by factors of 3.0 in each direction.
In the null case, for nominal 5% tests, the actual significance level of our test
was 3.9%, while the actual significance levels of the main effects test that set γ = 0
was 5.2%. For power calculations, the alternative values of the function were given
as θ(z) = c sine(2z) for c = 0.125, 0.250, 0.375.
The results are given in Figure 1. It is evident that our method has near-nominal
level, little power loss in the main effects only case (γtrue = 0), and considerable power
gain when there is an interaction.
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Figure 1. Results on power and level in the simulation for testing whether θ(·) is
constant.
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Because of the Wilks phenomenon and the similarity between kernel regression
and penalized spline regression, we also implemented the tests using penalized 2nd-
order B-splines with equally spaced knots and 10 basis functions. Because our theory
for kernel regression assumes that the same bandwidth is used for all values of γ,
the penalty parameter was chosen with γ = 0 using GCV (Ruppert, et al., 2003).
In fitting the non-null method, for any given γ we obtained estimates of β and θ(·)
by maximizing the loglikelihood function penalized by −(λ/2)ζTKζ , where λ is the
penalty parameter chosen as above, B(z) are the basis functions, θ(z) = BT(z)ζ , and
K is the penalty matrix. The results were almost identical to the kernel method.
D. Data Example
The data comes from a case-control study in Chatterjee et al. (2006). This study
investigates the association between colorectal adenoma, a precursor of colorectal
cancer, and NAT2, a candidate gene that is known to play an important role in
detoxification of certain aromatic carcinogens in cigarette smoke. In our data set, we
removed the nonsmokers, leaving 328 cases and 372 controls who were genotyped for
six known functional polymorphisms related to NAT2 acetylation activity.
Maity et al. (2009) considered an application involving the three most common
NAT2 diplotypes in comparison to the rest, which in our notation is X . The de-
mographic variables S include gender and three indicator dummy variables for age
level: between 60 and 65 years, between 65 and 70 years and more than 70 years.
We explored three different environmental variables Z, namely CIG STOP, the num-
ber of years since stopping smoking, PhIP, 2-Amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine, which has been demonstrated to produce adenocarcinomas in mice, and
Red Meat, daily grams of red meat intake.
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The results are displayed in Table 1. We see that in all cases, the p-values using
our method are smaller than that when γ is fixed to = 0. This is not a theorem of
course, but it does show support with the results of the simulations, which indicate
that if there is an interaction, our method will have greater statistical power.
Table 1. Significance levels in the NAT2 example
Number of
Environment Diplotypes Our Method Fixing γ = 0
CIG STOP 1 0.000 0.000
2 0.000 0.000
3 0.000 0.001
Red Meat 1 0.464 0.639
2 0.381 0.595
3 0.470 0.623
PhIP 1 0.984 0.935
2 0.227 0.939
3 0.162 0.938
E. Discussion
We have shown how to test for a constant environmental effect in the model (2.2).
The methodology was described for kernel regression methods and justified in the
important logistic regression case. Numerically, we have found that regression spline
approaches are very close to being the same as kernel methods and much faster to
compute, although their theory remains an open question in this context.
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CHAPTER III
LOCALLY EFFICIENT SCORE TESTS FOR INDEPENDENCE IN THE
SECONDARY ANALYSIS OF CASE-CONTROL DATA
Typical case-control studies focus on the relationship between disease D and covari-
ates (Y,X). In the secondary analysis of case-control data, it is the relationship
between Y and X that is of interest, but the analysis of this relationship is compli-
cated by the case-control sampling framework, which is a type of biased sampling.
Previous work has assumed a parametric distribution for Y given X and derived semi-
parametric efficient estimation and inference without any distributional assumptions
about X : of course, the roles of X and Y can be interchanged.
In this study, we take up the issue of score testing for the independence of X and
Y . The semiparametric efficient approaches can be used to construct semiparametric
score tests, but they suffer from a lack of robustness to the assumed model for Y given
X . We take an entirely different and novel approach. We show how to adjust the
semiparametric score test to make its level/Type I error asymptotically correct in the
rare disease case even if the assumed model for Y given X is incorrect, and thus the
test is model robust. Extensions to linear regression with additional covariates are
discussed. Simulations and an empirical example are used to illustrate the approach.
A. Introduction
Suppose that data are originally collected from a case-control study of a relatively
rare disease. Let D be disease status, with D = 1 denoting a case and D = 0
denoting a control. Suppose also that D is to be modeled by covariates (Y, Z,X)
using a standard logistic regression formulation.
There is growing awareness that such case-control data can also be exploited to
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understand various facets of the relationship among (Y, Z,X). Although we deal with
many different types of models, it is instructive to consider simpler cases in order to
fix ideas. For example, suppose that one would like to model Y by (Z,X) using a
homoscedastic additive regression model
Y = g1(Z, ξ) + g2(X, β) + ǫ, (3.1)
where g1(·) and g2(·) are known functions, and where ǫ has mean zero and variance σ2
in the population, and is independent of (Z,X), but its distribution is otherwise not
specified. Suppose we are further interested in knowing whether X is an independent
predictor of Y given Z. We can formalize this by testing whether β = 0.
We cannot simply ignore the case-control sampling scheme and use the data as
is to test the hypothesis that β = 0, because if (Y,X) are independent predictors
of disease status D, the sampling is biased and in the case-control sample X is an
independent predictor of Y . However, since the disease is rare, to a surprisingly
good approximation we can test this hypothesis by simply using only the controls
in the study. Strictly speaking this is asymptotically incorrect, but in practical data
situations even with 5, 000 cases and 5, 000 controls, the level/Type I error of a
regression test that uses the controls is very close to nominal.
The question we address here is whether in model (3.1) we can use both the
cases and the controls to construct a test with greater power than using the controls
only, without making strong distributional assumptions about the distribution of the
experimental errors ǫ.
This chapter is organized as follows. In Section B, we start with the basic general
problem that the covariates are simply (Y,X) and the interest is in knowing whether
X is a predictor of Y . Here we describe recent work on case-control studies that allows
an efficient score-test based solution if the distribution of Y given X is specified up to
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parameters. While the solution is elegant, it suffers from the fact that the resulting
test does not have the correct level if the hypothesized distribution for Y given X is
misspecified, a fact we show both theoretically and in simulations (Section E).
Section C takes an entirely different and novel approach to the basic general
problem, and describes a simple score-type test that is robust to misspecification of
the distribution of Y given X . In Section D, we return to model (3.1) and describe
a robust score-type test for the hypothesis that β = 0. Section E presents a series of
simulation studies, while Section F presents a data analysis. Concluding remarks are
in Section G.
B. Efficient Parametric Methods and Robustness
1. Framework
Before eventually providing a solution for model (3.1), here we consider the general
problem that the covariates are (Y,X) and we wish to test whether Y and X are
independent. We start with a logistic regression model underlying the case-control
analysis, so that pr(D = 1|Y,X) = H{θ0 +m(Y,X, θ1)}, where H(·) is the logistic
distribution function and m(·) is an arbitrary known function with unknown param-
eter θ1. Let πd = pr(D = d), and suppose there are n1 cases with D = 1 and n0
controls with D = 0. Write n = n0 + n1 and define κ = θ0 + log(n1/n0)− log(π1/π0).
Parametric models start with a density/mass function for Y given X , written as
fY (y, x, β, ζ), where β = 0 means that Y and X are independent, and ζ is a nuisance
parameter.
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2. Prior Results and Robustness
For this problem, Jiang, et al. (2006), Chen, et al. (2008) and Lin and Zheng (2009)
derive the efficient profile likelihood, the latter importantly realizing that it can be
used in our context. We use the notation of Chen, et al. (2008), and instead of
proving formulae for the general case, we here provide formulae only for the rare
disease case, the subject of this study. Define Ω = (κ, θ1) and
Spar(d, y, x,Ω, β, ζ) = fY (y, x, β, ζ) exp[d{κ+m(y, x, θ1)}]. (3.2)
The previous authors show that the semiparametric efficient profile likelihood that
makes no assumptions about the distribution of X when the distribution of Y given
X is specified is, in the rare disease case, given by
Lpar(D, Y,X,Ω, β, ζ) = Spar(D, Y,X,Ω, β, ζ)∫ ∑1
d=0 Spar(d, t, X,Ω, β, ζ)dt
.
Define L(y, x, ζ) = [∂log{fY (y, x, β, ζ)}/∂β]β=0. Then the score function for β evalu-
ated at the null hypothesis β = 0 is
Kpar(Y,X,Ω, ζ) = ∂log{Lpar(Y,X,Ω, β, ζ)}
β
∣∣
β=0
= L(Y,X, ζ)−
∫ ∑1
d=0L(t, X, ζ)Spar(d, t, X,Ω, 0, ζ)dt∫ ∑1
d=0 Spar(d, t, X,Ω, 0, ζ)dt
. (3.3)
Because Lpar(·) is a legitimate semiparametric profile likelihood, when summed over
the case-control data, the score statistic (3.3) has mean zero under our rare disease
assumption. Implementation of course involves estimating Ω. This can be done either
by maximizing the profile likelihood when β = 0 or much more easily from a logistic
regression of D on (Y,X), because this yields a consistent estimate of Ω.
In the Appendix B, we show that if the distribution of Y given X is misspeci-
fied, even under the null hypothesis of independence between (Y,X), then the score
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statistic does not in general have mean zero, and hence the score test is not model
robust. This motivates our search for a robust score-type test, a topic we take up in
the next section.
C. A Locally Efficient Robust Score Test
1. Preliminaries
First, in all our calculations and methods, we will estimate Ω consistently by a logistic
regression of D on the covariates.
Now that we know that the semiparametric efficient score test is not robust to
misspecification of the distribution of Y given X , we take up the topic of finding a
robust test. The approach is entirely different from that described in Section 2.
We start with a conjectured model for Y given X , e.g., see just above (3.3). Let
L(Y,X, ζ) be the null hypothesis score for this conjectured model. The idea is to
center this null score at its expectation, where the expectation is computed without
any modeling assumptions about Y . Remember that Ω = (κ, θ1), write the density
function of X as fX(·) and write the density function of Y under the null hypothesis
generically as fY (·). For the moment we will assume that fX(·) is known. Interest
is in testing whether Y and X are independent in the population, with data from a
case-control study. Define
S(d, y, x,Ω) = exp[d{κ+m(y, x, θ1)}]. (3.4)
Of course, (κ, θ1) can be estimated via ordinary logistic regression.
Under the hypothesis of independence, if Y is a continuous random variable,
Spinka, et al. propose to pretend that it is discrete with support at the observed Yi,
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pretending that
pr(Y = Yi) = pest(Yi) =
nπ0
n0
n−1
{∫
fX(x)
∑1
d=0S(d, Yi, x,Ω)dx
}−1
. (3.5)
Strictly speaking, this is only true when Y has a continuous density function, but in
what follows we use (3.5) in such a way that our methods apply to the discrete case.
2. The Theoretical Score Under the Null Hypothesis
To derive the method, we consider the alternative formulation (Chen, et al., 2009) of
case-control studies as random samples with missing data: of course, we use the only
for intuition, and do all technical calculations in the actual case-control study. In this
alternative formulation, we have random sampling and we observe (D, Y,X), which
we write as δ = 1, with pr(δ = 1|D = d, Y,X) ∝ nd/nπd. Then, in this formulation
∑1
d=0pr(D = d, Y = y,X = x|δ = 1)
=
{(nd/(nπd)}pr(D = d|Y = y,X = x)pr(Y = y|X = x)fX(x)∑1
p=0{np/(nπp)}
∫
pr(D = p|Y = t, X = v)pr(Y = t|X = v)fX(v))dtdv
=
∑1
d=0S(d, y, x,Ω)fY (y, x, β, ζ)fX(x)∑1
p=0
∫
S(p, t, v,Ω)fY (t, v, β, ζ)fX(v)dtdv
. (3.6)
Then the score for β in this alternative formulation calculated under the null hypoth-
esis is
L(Y,X, ζ)−
∑1
d=0
∫
L(t, x, ζ)S(d, t, x,Ω)fY (t)fX(x)dtdx∑1
d=0
∫
S(d, t, x,Ω)fY (t)fX(x)dtdx
. (3.7)
The problem of course is that we do not know the form of fY (·), so that the test
statistic (3.7) cannot be implemented. The idea is to replace fY (·) in (3.7) by the
23
discrete distribution (3.5), leading to the test statistic
V(Ω) = n−1∑ni=1L(Yi, Xi, ζ)
−
∑n
i=1
∑1
d=0
∫
L(Yi, x, ζ)S(d, Yi, x,Ω)pest(Yi)fX(x)dx∑n
i=1
∑1
d=0
∫
S(d, Yi, x,Ω)pest(Yi)fX(x)dx
. (3.8)
We now show how to simplify this test statistic, that it has mean zero under the null
hypothesis even if the model for Y is misspecified under the null hypothesis, and that
it does not have mean zero in general at alternatives.
Theorem 1 Define
U(Y,Ω, ζ) =
∑1
d=0
∫
L(Y, x, ζ)S(d, Y, x,Ω)fX(x)dx∑1
d=0
∫
S(d, Y, x,Ω)fX(x)dx
. (3.9)
Then the test statistic V in (3.8) satisfies
V(Ω, ζ) = n−1∑ni=1{L(Yi, Xi, ζ)− U(Yi,Ω, ζ)}. (3.10)
In addition, if fX(·) is specified correctly, the score test statistic (3.10) has mean zero
in the case-control sampling scheme under the null hypothesis, but in general does not
have mean zero at alternatives.
3. Practical Implementation and Asymptotic Theory
In order to implement the test statistic (3.10), we have to estimate Ω = (κ, θ1), ζ if
applicable, and fX(·). We do this as follows.
• It is well known that Ω = (κ, θ1) can be estimated consistently by ordinary
logistic regression of D on (Y,X), and this is the estimate we use.
• The proof of Theorem 1 shows that as long as an estimate ζ̂ is converging at the
rate Op(n
−1/2) to some value ζ∗, the robust score V(Ω̂, ζ̂) will converge to zero
under the null hypothesis. Based on the rare disease assumption, estimation of
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ζ can be performed conveniently by using only the controls in the study, and
doing the estimation under the null hypothesis using the conjectured model
fY (y, x, β = 0, ζ).
• To estimate fX(·), we use the rare disease assumption, namely that fX(·) =
fX,cont(·), then density of X among the controls. Then the integrals in (3.9) can
be estimated unbiasedly as averages among the controls.
With these conventions, the test statistic becomes
V(Ω̂, ζ̂) = n−1∑ni=1L(Yi, Xi, ζ̂)
−n−1∑ni=1n−10
∑n
j=1(1−Dj)L(Y,Xj, ζ̂)S(d, Y,Xj, Ω̂)
n−10
∑n
j=1(1−Dj)S(d, Y,Xj, Ω̂)
. (3.11)
We sketch a proof of the followings result in Appendix B, which uses U-statistic
theory.
Theorem 2 Assume that as n→∞, n0/n1 → c, where 0 < c <∞. There is a func-
tion Λ(Y,X,Θ) defined in the Appendix B with the property that E{Λ(Y,X,Θ)|D} = 0
such that under the null hypothesis,
n1/2V(Ω̂, ζ̂) = n−1/2∑ni=1Λ(Yi, Xi,Θ) + op(1)
→ Normal(0,Σ);
Σ =
∑1
d=0(nd/n)cov{Λ(Y,X,Θ)|D = d}.
We also show in Appendix B how to estimate Σ by method of moment calcula-
tions, although we find it simpler to estimate it by using the bootstrap, resampling
the cases and controls separately. With an estimate Σ̂, under the null hypothesis
nVT(Ω̂, ζ̂)Σ−1V(Ω̂, ζ̂) is asymptotically χ2p, where p = dim(β), and the hypothesis of
independence can be tested by referring to chisquared percentile
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D. The Regression Case
We now return to model (3.1). We see that under the null hypothesis β = 0,
X is independent of Y − g1(Z, ξ), where now the nuisance parameter in our gen-
eral formulation is ζ = ξ. Hence, all of our previous results apply if L(Y,X, ζ) =
{∂g2(X, β)/∂β}β=0{Y − g1(Z, ξ)}, and, using the rare disease approximation, the
nuisance parameter ξ is estimated from the regression of Y on Z among the controls.
E. Simulation Studies
We performed a series of simulation studies both at and away from an hypothesized
normal model, with X binary, discrete and continuous. In general we will show that
our proposed test statistic has near nominal level (Type I error) in all cases, while an
implementation of the efficient test does not. We also show that while the test that
uses only the controls has near nominal level, our method has much greater power.
1. When X is Binary
Our first simulation occurs when X is binary. Here we consider the case of a genotype,
with minor allele frequency pA = 0.10, and with genotypes generated under Hardy
Weinberg Equilibrium. Assuming a dominant mode of inheritance, we have X as
binary with pr(X = 0) = (1 − pA)2 = 0.81. The regression model for Y given X
was taken as Y = β0 + β1X + ǫ, with β0 = 0. We considered three distributions for
ǫ. The hypothesized model was Normal(0, σ2) with σ2 = 1. The misspecified models
were (a) Chisquared(7) centered and standardized to have mean zero and variance
one; and (b) centered and standardized Gamma(a, b), where a = (0.4, 0.8, 1.4, 1.8)
and b = 1.9. The logistic regression model has m(Y,X, θ1) = θ11Y + θ12X , with
θ11 = 0.25 and θ12 = 1. The value of θ0 = −3.50 was chosen so that the rate of
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disease in the population for the normal case was π1 = 0.045. The case-control study
had n1 = 500 cases and n0 = 500 controls. We generated 1, 000 simulated data sets.
Values β1 = 0.00 for the null hypothesis and β1 = (0.10, 0.15, 0.20, 0.30, 0.40, 0.50)
were taken to investigate level and power. We made the rare disease assumption,
so that Ω = {κ, θ1 = (θ11, θ12)}, and Ω was estimated by ordinary linear logistic
regression of D on (Y,X).
Here ζ = (β0, σ
2). We compared the efficient score test that assumes that Y =
Normal(β0+β1X, σ
2) but make no assumptions about the distribution of X with the
robust method described, where for the former ζ was estimated efficiently at the null
hypothesis using the controls. In both cases, the variance of the score statistic was
estimated by 400 bootstrap samples. We use the rare disease assumption.
For the robust test, Ω = {κ, θ1 = (θ11, θ12)}, ζ = (β0, σ2), fY (y, x, β, ζ) =
(2πσ2)1/2φ{(y − β0 − xβ1)/σ} and L(y, x, ζ) = [∂log{fY (y, x, β, ζ)}/∂β]β=0 = (y −
β0)x/σ
2, where φ(·) is the standard normal density function. We estimated β0 as the
mean of Y among the controls, and estimate σ2 as the mean squared error of the
linear regression of Y on X among the controls.
For the efficient test, the score function for β1 evaluated at the null hypothesis
β1 = 0 is
Kpar(y, x,Ω, ζ) = L(y, x, ζ)−
∫ ∑1
d=0L(t, x, ζ)Spar(d, t, x,Ω, 0, ζ)dt∫ ∑1
d=0 Spar(d, t, x,Ω, 0, ζ)dt
.
Rather than implement the efficient Wald test, which requires repeated numerical
integration, we instead estimate (Ω, ζ) as described above. Then, by simple algebra,
the score for β1 evaluated at β1 = 0 is proportional to
Tpar(y, x,Ω, ζ) = xy − x
∫ ∑1
d=0tSpar(d, t, x,Ω, 0, ζ)dt∫ ∑1
d=0 Spar(d, t, x,Ω, 0, ζ)dt
. (3.12)
In the Appendix B, we show how to compute (3.12) exactly without numerical integra-
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tion. The score test statistic then becomes Vpar(Ω̂, ζ̂) = n−1/2
∑n
i=1 Tpar(Yi, Xi, Ω̂, ζ̂).
In Table 2, the first two columns show the test levels of the robust test and
efficient score test with different distributions of ǫ. The robust test has near nominal
level in all cases, as expected by the theory. Also as expected, the level of the efficient
test is near nominal at the correctly specified normal distribution, but at the various
Gamma distributions it has inflated Type I error.
There are of course alternative methods. One is to ignore the case-control sam-
pling scheme entirely, and simply regress Y on X in the study data. As expected, this
has inflated level in all cases, see Table 2. An alternative is to use the rare-disease
assumption and regress Y on X among only the controls. Table 2 shows that this
procedure has near-nominal level in all cases. However, unlike our method, it uses
only 1/2 the data, and would be expected to suffer from lower power. In Table 3, we
compare the power of our method to this regression of Y on X among the controls,
both for the normal case and also one of the Gamma cases. In both, our method,
while equally robust in terms of test level, has much greater power.
Table 2. Test levels of normal, chisquared and gamma distributions for three methods
when X is binary
Score
Robust Efficient Regression Regression(c) pr(D = 1)
Normal(0,1) 0.054 0.062 0.088 0.047 0.045
Chisquared(7) 0.050 0.051 0.069 0.048 0.048
G(0.4,0.9109) 0.049 0.100 0.093 0.045 0.039
G(0.8,0.9109) 0.047 0.125 0.104 0.035 0.039
G(1.4,0.9109) 0.065 0.097 0.082 0.053 0.039
G(1.8,0.9109) 0.056 0.105 0.077 0.034 0.039
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Table 3. Powers of normal and gamma distributions when X is binary
β1 0.1 0.15 0.2 0.3 0.4 0.5
Robust Normal(0,1) 0.183 0.381 0.698 0.951 0.999 1.000
G(1.8,0.9) 0.150 0.316 0.537 0.926 0.998 1.000
Regression Normal(0,1) 0.102 0.177 0.316 0.636 0.875 0.977
G(1.8,0.9) 0.113 0.225 0.375 0.685 0.927 0.991
2. When X is Discrete
We next performed a similar simulation, with the only change being that X is dis-
crete with support points (−0.40, 0.15, 1.00, 1.30, 2.10), with respective probabilities
(0.04, 0.08, 0.16, 0.41, 0.31). We chose θ0 = −4.68 so that the probability of disease is
about 0.04.
The gain in power over the method that regresses Y on X among the controls is
demonstrated in Table 4. Table 5, shows that the robust test performs much better
than the efficient score test in terms of test level when the distribution of Y given X
is misspecified.
Table 4. Powers of normal and gamma distributions when X is discrete
β1 0.1 0.15 0.2 0.3 0.4 0.5
Robust Normal(0,1) 0.416 0.747 0.872 0.997 1.000 1.000
G(1.8,0.9) 0.443 0.768 0.884 0.994 1.000 1.000
Regression Normal(0,1) 0.272 0.524 0.811 0.989 1.000 1.000
G(1.8,0.9) 0.270 0.564 0.812 0.990 1.000 1.000
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Table 5. Test levels of normal, chisquared and gamma distributions for three methods
when X is discrete
Score
Robust Efficient Regression Regression(c) pr(D = 1)
Normal(0,1) 0.055 0.067 0.124 0.041 0.041
Chisquared(7) 0.053 0.089 0.157 0.061 0.042
G(0.4,0.9109) 0.031 0.398 0.156 0.053 0.042
G(0.8,0.9109) 0.041 0.257 0.143 0.053 0.042
G(1.4,0.9109) 0.036 0.173 0.140 0.061 0.042
G(1.8,0.9109) 0.041 0.133 0.153 0.058 0.042
3. When X is Continuous and Scalar
We formed a similar simulation as in the discrete case, with the only change being
that X is generated as Uniform(0, 1). We chose θ0 = −3.7 so that the probability
of disease is about 0.04. The gain in power over the method that regresses Y on
X among the controls is demonstrated in Table 6. Table 7, shows that the robust
test performs much better than the efficient score test in terms of test level when the
distribution of Y given X is misspecified.
Table 6. Powers of normal and gamma distributions when X is continuous
β1 0.1 0.15 0.2 0.3 0.4 0.5
Robust Normal(0,1) 0.131 0.235 0.367 0.700 0.925 0.994
G(1.8,0.9) 0.104 0.190 0.315 0.650 0.881 0.979
Regression Normal(0,1) 0.102 0.159 0.250 0.494 0.704 0.890
G(1.8,0.9) 0.090 0.144 0.225 0.461 0.720 0.893
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Table 7. Test levels of normal, chisquared and gamma distributions for three methods
when X is continuous
Score
Robust Efficient Regression Regression(c) pr(D = 1)
Normal(0,1) 0.053 0.057 0.067 0.056 0.042
Chisquared(7) 0.041 0.082 0.069 0.049 0.042
G(0.4,0.9109) 0.052 0.378 0.083 0.048 0.042
G(0.8,0.9109) 0.042 0.398 0.074 0.056 0.042
G(1.4,0.9109) 0.046 0.385 0.079 0.059 0.042
G(1.8,0.9109) 0.047 0.396 0.067 0.041 0.042
4. Model with Covariates
In this section we add a covariate Z in our model since in practice we always have
covariates. We generate Z as Uniform(0, 1). The regression model for Y given (X,Z)
was then taken as Y = β0 + β1X + β2Z + ǫ, with β0 = 1 and β2 = 0.5. We use
the controls to run the regression of Y on Z to estimate ζ = (β1, β2), then call
Y∗ = Y − ξˆ0− ξˆ1Z, the residuals, and run the test as if Y∗ were our response. We got
similar results as the without covariates case in terms of test levels and power.
F. Applications
We analyze two gene (X) environment (Y ) interaction data sets, one in which Y and
X are thought to be independent, and the other in which Y and X are thought to
be related.
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1. Prostate Cancer Example
Chen, et al. (2009) investigate a case-control study of prostate cancer. The sample
includes 749 prostate cancer cases and 781 controls, also selected from the screening
arm of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
at the National Cancer Institute, USA (Gohagan, Prorok, Hayes, and Kramer 2000;
Moslehi et al. 2006). The main objective of the study is to examine the relationship
between risk of prostate cancer and [25(OH)D], a serum level biomarker of vitamin
D, that reflects both dietary and sunlight exposures. The anticancer effect of vi-
tamin D is hypothesized due to the ability of prostate cells to convert [25(OH)D)]
into 1,25-dihydroxy-vitamin D [1,25(OH)2D], the most active form of this vitamin,
which regulates the gene transcription of many proteins involving cellular differenti-
ation, proliferation, and apoptosis via the vitamin D receptor (VDR). Chen, et al.
(2009) write ”Given the downstream role of the VDR gene in the vitamin-D path-
way, it is very unlikely that these polymorphisms actually could influence the level of
the [25(OH)D] itself. Thus, the gene-environment independence assumption in this
application is likely to be valid”.
The notation of this chapter, D is the prostate cancer case-control status, Y is
the level of 1,25-dihydroxy-vitamin D and X is one of three SNP, and Z is age level
categorized into four groups and hence with three dummy variables. The quote above
suggests that Y and X are independent in the population, and hence our test should
find no evidence that any of the SNP are related to 1,25-dihydroxy-vitamin D level.
Indeed, this is the case: all p-values are greater than 0.35, as expected.
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2. Colorectal Adenoma
Chen, et al. also discuss a case-control study of colorectal adenoma, a precursor of
colorectal cancer. The study sample includes 628 prevalent advanced adenoma cases
and 635 gender-matched controls, also selected from the screening arm of the PLCO
Study. One of the main objectives of this study is to assess whether the smoking-
related risk of colorectal adenoma may be modified by certain haplotypes in NAT2,
a gene known to be important in the metabolism of smoking related carcinogens. In
addition, because NAT2 is involved in the smoking metabolism pathway, potentially it
can influence an individuals addiction to smoking itself, causing the gene-environment
independence assumption to be violated. In other words, hereD is colorectal adenoma
status, Y are various measures of smoking status, and X are various haplotypes.
Chen, et al. use Z as age in years and gender. They claim that it is reasonable to
suppose that in the population, Y and X are related.
The smoking variables used here are (a) years since stopping smoking censor at
45; (b) Number of packs smoked per day; and (c) pack years subtract 0.25 and censor
at 100, i.e., packs per day times years smoked. As in Maity, et al. (2009), we let X
be the indicator of the most common diplotype.
The results are given in Table 8. We see a statistically significantly protective
of the most common diplotype for the years since stopping smoking. Crucially, all
the p-values from the robust test are similar to those from regression among controls
only, and are much less than those from the efficient score test. This is not a theorem
of course, but it does show support with the results of the simulations, which indicate
that the efficient score test can have the wrong level if the distribution of Y given X
is misspecified. We also randomly sub-sampled 80% of the people 1,000 times for the
smoking variable (a), and found that 61.2% of times our test rejected the null, while
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the regression among controls rejected the null 34.9% of times. This indicated our
test will have great gain in statistical power over the method that regresses Y on X
among the controls.
Table 8. P-values in the NAT2 example
Environment Robust Non-Robust Regression
CIG STOP 0.041 0.081 0.036
PACK YEARS 0.215 0.364 0.243
PACK DAY 0.198 0.382 0.227
G. Discussion
The study of the relationship among secondary variables in a case-control study is
of great practical interest, because large case-control studies now exist and especially
include predictors or phenotypes Y and demographic, environmental and genetic
factors. As we have noted, the semiparametric efficient approaches can be used to
construct semiparametric score tests, but they suffer from a lack of robustness to
the assumed model for Y given X : it is possible to create skew distributions for the
regression errors that result in bias when normality is assumed.
Our approach is entirely different. While we specify a target regression error
distribution, we have shown that the test procedure is robust to violation of that
target distribution, both theoretically and in a simulation study. In the rare disease
case that would be the reason for a case-control study in the first place, an alternative
is to simply use only the data for the controls. We have shown in simulations and in
our two data examples that such throwing away of 50% of the data leads to a highly
non-trivial loss of power compared to our method.
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CHAPTER IV
LOCALLY EFFICIENT ESTIMATION FOR HOMOSCEDASTIC REGRESSION
IN THE SECONDARY ANALYSIS OF CASE-CONTROL DATA
Typical case-control studies focus on the relationship between disease D and covari-
ates (Y,X). In the secondary analysis of case-control data, it is the relationship be-
tween Y and X that is of interest, but the analysis of this relationship is complicated
by the case-control sampling framework. Previous work has assumed a paramet-
ric distribution for Y given X and derived semiparametric efficient estimation and
inference without any distributional assumptions about X .
In this project, we take up the issue of estimation of a regression function when
Y given X follows a homoscedastic regression model. The semiparametric efficient
approaches can be used to construct semiparametric efficient estimates, but they suffer
from a lack of robustness to the assumed model for Y given X . We take an entirely
different and novel approach in the case that the disease is rare. We show how to
estimate the regression parameters in the rare disease case even if the assumed model
for Y given X is incorrect, and thus the estimates are model-robust. Simulations and
an empirical example are used to illustrate the approach.
A. Introduction
Suppose that data are originally collected from a case-control study of a relatively
rare disease. Let D be disease status, with D = 1 denoting a case and D = 0 denoting
a control. Suppose also that D is to be modeled by covariates (Y,X) using a standard
logistic regression formulation.
There is growing awareness that such case-control data can also be exploited to
understand various facets of the relationship among (Y,X). We consider here the
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homoscedastic regression model
Y = αtrue + µ(X, βtrue) + ǫ, (4.1)
where αtrue is an intercept, µ(·) is a known function, and where ǫ has mean zero and
is independent of X , but its distribution is otherwise not specified.
To estimate (αtrue, βtrue), we cannot simply ignore the case-control sampling
scheme and use the data as is, because if X is an independent predictor of dis-
ease status D, the sampling is biased and in the case-control sample model (4.1) will
not hold. However, since the disease is rare, to a surprisingly good approximation we
can indeed use only the controls and obtain an approximately consistent estimate.
The question we address here is whether in model (4.1) we can use both the cases
and the controls to construct more efficient estimates of (αtrue, βtrue) than using the
controls only, at the same time without making distributional assumptions about the
distribution of the experimental errors ǫ.
This chapter is organized as follows. In Section B, we describe recent work on
case-control studies that allows efficient estimation if the distribution of Y given X
is specified up to parameters. While the solution is elegant, it suffers from the fact
that the resulting estimate is biased if the hypothesized distribution for Y given X is
misspecified.
Section C takes an entirely different approach to the basic general problem, and
describes a simple method that is robust to misspecification of the distribution of Y
given X . Section D presents a series of simulation studies, while Section E presents
a data analysis. Concluding remarks are in Section F. Technical details are given in
an appendix.
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B. Efficient Parametric Methods and Robustness
1. Framework
We start with a logistic regression model underlying the case-control analysis, so
that pr(D = 1|Y,X) = H{θ0 +m(Y,X, θ1)}, where H(·) is the logistic distribution
function and m(·) is an arbitrary known function with unknown parameter θ1. Let
πd = pr(D = d), and suppose there are n1 cases with D = 1 and n0 controls with
D = 0, write n = n0 + n1 and define κ = θ0 + log(n1/n0) − log(π1/π0). Write the
parametric model for Y given X as fǫ{y − µ(x, β), ζ}. If in the population Y given
X is normally distributed, then ζ = var(ǫ).
2. Prior Results and Robustness
For this problem, Jiang, et al. (2006), Chen, et al. (2008) and Lin and Zheng (2009)
derive the efficient profile likelihood, the latter noting importantly that it can be used
in our context. We use the notation of Chen, et al. (2008), and instead of proving
formulae for the general case, we here provide formulae only for the rare disease case,
the subject of this study. Define Ω = (κ, θ1) and
Spar(d, y, x,Ω, α, β, ζ) = fǫ{y − α− µ(x, β), ζ} exp[d{κ+m(y, x, θ1)}]. (4.2)
The previous authors show that the semiparametric efficient profile likelihood that
makes no assumptions about the distribution of X when the distribution of Y given
X is specified is
Lpar(D, Y,X,Ω, α, β, ζ) = Spar(D, Y,X,Ω, α, β, ζ)∫ ∑1
d=0 Spar(d, t, X,Ω, α, β, ζ)dt
.
Taking logarithms, summing over the observed data and then maximizing in the
parameters yields semiparametric efficient inference. A difficulty arises however if the
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density fǫ(·) of ǫ is not specified properly.
To see what happens, we consider the score for β. Define Lpar(y, x, α, β, ζ) =
∂log[fǫ{y − α− µ(x, β), ζ}]/∂β. Then the score for β is
Kpar(D, Y,X,Ω, α, β, ζ) = ∂log{Lpar(D, Y,X,Ω, α, β, ζ)}
∂β
(4.3)
= Lpar(Y,X, α, β, ζ)
−
∫ ∑1
d=0 Lpar(t, X, α, β, ζ)Spar(d, t, X,Ω, α, β, ζ)dt∫ ∑1
d=0 Spar(d, t, X,Ω, α, β, ζ)dt
.
Because Lpar(·) is a legitimate semiparametric profile likelihood, when summed over
the case-control data and evaluated at the true parameters, the score (4.3) has mean
zero under our rare disease assumption. Unfortunately, (4.3), when evaluated at
the true parameter values, only has mean zero in general if the density fǫ(·) of ǫ is
specified properly, i.e., the approach is not model robust. This motivates our search
for a robust estimation method, a topic we take up in the next section.
C. Model-Robust Estimation
1. Preliminaries
Our method involves a multi-step process.
• Estimate the logistic regression parameters Ωtrue by ordinary logistic regression
of D on (Y,X). This can be done legitimately because it is well known that
ordinary logistic regression in a case-control study consistently estimates Ωtrue.
Call the result Ω̂.
• Write a conjectured version of the model for Y given X . In our case, we conjec-
ture a normal distribution with constant variance ζ . In general, we conjecture
a distribution where ǫ depends on a nuisance parameter ζ .
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• Compute the score function of the conjectured model for β and ζ . In the normal
case that we pursue, define R(β) = Y −µ(X, β) in which case the score function
for the conjectured model is proportional to ζ , which can be ignored, and hence
is
L{R(β), X, α, β} = µβ(X, β){R(β)− α}, (4.4)
where the subscript means differentiation with respect to β.
• The score (4.4) will not have mean zero in the case-control sampling scheme, so
we adjust it so that it has mean zero in general, even if the conjectured model
is not correct.
• For technical reasons described later, estimation of αtrue has to be done via an
auxiliary equation depending on the current values, which we generically call
α̂(β, Ω̂), which replaces α in the score (4.4), see below for the definition.
• Solve the adjusted score equation to estimate βtrue and hence αtrue. Good start-
ing values for β can be obtained by least squares regression among the controls.
2. The Methodology
The development of our methodology is somewhat involved. Here we simply state
our proposal, with its development given in subsequent subsections. As before, de-
fine R(β) = Y − µ(X, β) and define K{Ri(β), x, β,Ω} = 1 + exp[κ + m{Ri(β) +
µ(x, β), x,Ω}]. Let
α̂(β,Ω) =
n−1
∑n
i=1Ri(β){n−10
∑n
j=1(1−Dj)K{Ri(β), Xj, β,Ω}}−1
n−1
∑n
i=1{n−10
∑n
j=1(1−Dj)K{Ri(β), Xj, β,Ω}}−1
. (4.5)
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Let µβ(x, β) = ∂µ(x, β)/∂β and let L{R(β), X, α, β} be as in (4.4). Then define
Q̂n,est(β,Ω) = n
−1/2
∑n
i=1
[
L{Ri(β), Xi, α̂(β,Ω), β} (4.6)
−n
−1
0
∑n
j=1(1−Dj)L{Ri(β), Xj, α̂(β,Ω), β}K{Ri(β), Xj, β,Ω}
n−10
∑n
j=1(1−Dj)K{Ri(β), Xj, β,Ω}
]
.
Our algorithm then is as follows.
• Estimate Ω by Ω̂, the logistic regression estimates of D on (Y,X). These are
known to produce consistent estimates of Ωtrue.
• Solve 0 = Q̂n,est(β, Ω̂) in β to obtain our estimate β̂.
In the next few subsections, we describe how we obtained (4.6), and at the end we
describe the asymptotic distribution theory.
3. Development of the Score when fX(·) and αtrue are Known
We first describe how to proceed when the intercept αtrue and the density fX(·) of X
in the population are known; of course they are not and we will show how to remove
these restrictions in subsequent sections. In what follows, we use the notation Ecc
as a short hand notation for expectation in the case-control sampling scheme. Thus,
Ecc{G(D, Y,X)} = n−1
∑n
i=1E{G(Di, Yi, Xi)|Di} =
∑1
d=0(nd/n)E{G(D, Y,X)|D =
d}.
To derive the method, we consider the alternative formulation (Chen, et al., 2009)
of case-control studies as random samples with missing data. Of course, we use this
only for intuition, and do all technical calculations in the actual case-control study.
In this alternative formulation, we have random sampling and we observe (D, Y,X),
thus setting the binary δ = 1, with pr(δ = 1|D = d, Y,X) ∝ nd/nπd. Then, in this
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formulation
pr(D = d, Y = y,X = x|δ = 1)
=
{(nd/(nπd)}pr(D = d|Y = y,X = x}pr{Y = y|X = x)fX(x)∑1
p=0{np/(nπp)}
∫
pr(D = p|Y = t, X = v)pr{Y = t|X = v}fX(v)dtdv
.
This means that the regression model in the alternative formulation is
pr(Y = y,X = x|δ = 1)
=
∑1
d=0(nd/πd)pr(D = d|Y = y,X = x}fǫ{y − αtrue − µ(x, β), ζ}fX(x)∑1
p=0(np/πp)
∫
pr(D = p|Y = t, X = v)fǫ{t− αtrue − µ(v, β), ζ}fX(v)dtdv
.
We now make the rare disease approximation so that
∑1
d=0(nd/πd)pr(D = d|Y =
y,X = x} = (n0/π0)+(n1/π1) exp{θ0+m(y, x, θ1)} = (n0/π0)[1+exp{κ+m(y, x, θ1)}].
If the conjectured model is the normal distribution, then we can drop the term ζ and
up to a constant of proportionality the score for β is
µβ(X, β){Y − αtrue − µ(X, β}
−
∫
µβ(v, β){t− αtrue − µ(v, β)}fǫ{t− αtrue − µ(v, β)}∫
fǫ{t− αtrue − µ(v, β)}[1 + exp{κ+m(y, v, θ1)}]fX(v)dtdv
×[1 + exp{κ+m(y, v, θ1)}]fX(v)dtdv.
We now make the change of variables R(β) = Y−µ(X, β), and recall thatK(r, x, β,Ω) =
1 + exp[κ+m{r + µ(x, β), x,Ω}]. Referring to (4.4), this means that the score for β
in the alternative formulation of Chen, et al. (2009) is
L{R(βtrue), X, αtrue, β} −
∫
L{t, x, αtrue, β}K(t, x, β,Ω)fǫ(t)fX(x)dtdx∫ K(t, x, β,Ω)fǫ(t)fX(x)dtdx . (4.7)
The problem of course is that we do not know the form of fǫ(·), so that the score
(4.7) cannot be implemented. Spinka, et al. address this issue, although not directly
in our context. Noting that R(βtrue) and X are independent, we propose to replace
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fǫ(·) by pretending that it is discrete with support at the observed Ri(β), so that
pr{R(β) = Ri(β)} = pest{Ri(β),Ω}
=
nπ0
n0
n−1
{∫
fX(x)K{Ri(β), x, β,Ω}dx
}−1
. (4.8)
When we make this substitution in (4.7) and sum over the data, the score becomes
∑n
i=1L{Ri(β), Xi, αtrue, β}
−
∑n
i=1
∫
L{Ri(β), x, αtrue, β}K{Ri(β), x, β,Ω}pest{Ri(β),Ω}fX(x)dx
n−1
∑n
i=1
∫ K{Ri(β), x, β,Ω}pest{Ri(β),Ω}fX(x)dx .
Because the denominator of this expression is π0/n0, by simple algebra is it readily
seen that the normalized score function for estimating β can be defined as
0 = Qn(αtrue, β,Ω) (4.9)
= n−1/2
∑n
i=1 [L{Ri(β), Xi, αtrue, β}
−
∫
L{Ri(β), x, αtrue, β}K{Ri(β), x, β,Ω}fX(x)dx∫ K{Ri(β), x, β,Ω}fX(x)dx
]
.
In Appendix C, we show that Ecc{Qn(αtrue, β,Ω)} equals zero when evaluated at
(αtrue, βtrue,Ωtrue), but not generally, and thus (4.9) is an unbiased estimating equation
in the case-control sampling scheme, and not just the alternative formulation.
Remark 1 If the conjectured model fǫ{y−αtrue−µ(x, β), ζ} is not the normal model,
then ζ must also be estimated. This can be done by replacing L{R(β), X, αtrue, β}
by ∂log[fǫ{Y − αtrue − µ(X, β), ζ}]/∂(β, ζ).
4. Implementation when fX(·) is Unknown but αtrue is Known
Of course, fX(·) is not known. Because the disease is rare, we propose to approximate
fX(·) by fX,cont(·), the density of X among the controls. We then estimate the inte-
grals in (4.9) unbiasedly by their averages among the controls, so that our estimating
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equation is
0 = Q̂n(αtrue, β,Ω) (4.10)
= n−1/2
∑n
i=1
[
L{Ri(β), Xi, αtrue, β}
−n
−1
0
∑n
j=1(1−Dj)L{Ri(β), Xj, αtrue, β}K{Ri(β), Xj, β,Ω}
n−10
∑n
j=1(1−Dj)K{Ri(β), Xj, β,Ω}
]
.
5. When the Intercept αtrue is Unknown
In most cases, the mean function will include an intercept, although of course our
methods are easily modified in case no intercept exists.
One might reasonably think that estimating the intercept is easy, e.g., simply
supplement the score with the score for the intercept, so that L{R(β), X, α, β} =
{1, µTβ (X, β)}T{R(β)− α}. The problem with this is that the first component of the
estimating equation (4.10) would then be identically zero, and thus will not produce an
estimate of the intercept. The reason for this is that the solution (4.8) was calculated
nonparametrically under the assumption that R(βtrue) and X are independent in the
population. Since Y − αtrue − XTβtrue and Y − XTβtrue are both independent of X
in the population, this means that (4.8) cannot lead to an estimate of the intercept.
Hence, an alternative approach is required.
To overcome this problem, we estimate the intercept of R(β) using the tilting
suggested by Spinka, et al., i.e., if fX(·) were known, then α could be estimated by
α̂1(β,Ω) =
n−1
∑n
i=1Ri(β)pest{Ri(β),Ω}
n−1
∑n
i=1pest{Ri(β),Ω}
,
a quantity that is free of the π0 that shows up in (4.8). If we then invoke the
rare disease approximation and replace the integral in the definition of pest(·) by its
therefore unbiased average n−10
∑n
j=1(1−Dj)K{Ri(β), Xj, β,Ω}, we get exactly (4.5).
Making this substitution in (4.10), we obtain (4.6). This completes the derivation of
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our methodology.
6. Distribution Theory
Let (Ω, β) = Θ, and let Θtrue denote its true value. Recall that fX,cont(·) is the density
function of X among the controls, and define
α(β,Ω) =
Ecc(R(β)[
∫
fcont(x)K{R(β), x, β,Ω}dx]−1)
Ecc([
∫
fcont(x)K{R(β), x, β,Ω}dx]−1) ;
T {R(β), X,Θ, fX,cont} = L{R(β), X, α(β,Ω), β}
−
∫
L{R(β), x, α(β,Ω), β}K{R(β), x,Θ}fX,cont(x)dx∫ K{R(β), x,Θ}fX,cont(x)dx
MΩ = Ecc
[
∂T {R(βtrue), X,Θtrue, fX,cont}
∂ΩT
]
;
Mβ = Ecc
[
∂T {R(βtrue), X,Θ, fX,cont}
∂βT
]
.
Define Gnum(r, x,Θ) = L{r, x, α(β,Ω)β}K(r, x,Θ) and Gden(r, x,Θ) = K(r, x,Θ) De-
fine Anum(r,Θ) = E{Gnum(r,X,Θ)|D = 0} and Aden(r,Θ) = E{Gden(r,X,Θ)|D =
0}. Define
Hn(β,Θ) = n−1/2
∑n
i=1
[
n−10
∑n
j=1(1−Dj)Gnum{Ri(β), Xj,Θ}
n−10
∑n
j=1(1−Dj)Gden{Ri(β), Xj,Θ}
− Anum{Ri(β),Θ}Aden{Ri(β),Θ}
]
.
Define
W{Ri(β), Xj, Dj,Θ}
= (1−Dj)Gnum{Ri(β), Xj,Θ} − Anum{Ri(β),Θ}Aden{Ri(β),Θ}
−(1−Dj)Anum{Ri(β),Θ}[Gden{Ri(β), Xj,Θ} − Aden{Ri(β),Θ}]A2den{Ri(β),Θ}
.
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Also define
c∗ = lim
n→∞
(n/n0);
Z˜i(β) = {Ri(β), Xi, Di};
z˜ = (r, x, d);
Q1{Z˜i(β), Z˜j(β),Θ) = W{Ri(β), Xj, Dj ,Θ}+W{Rj(β), Xi, Di,Θ};
Q2(z˜, β,Θ) = E[W{R(β), x, d,Θ}|D = 1];
h1(d, z˜, β,Θ) = E{Q1{z˜, Z˜(β),Θ}|D = d};
h2{Ri(β), Xi, Di,Θ} = c∗(n0/n)(1−Di)h1{Di, Z˜i(β), β,Θ}
+c∗(n1/n)(1−Di)Q2{Z˜i(β), β,Θ};
Φ(y, x, d,Ω) = {1, mΩ(y, x, θ1)}T[D −H{κ+m(y, x, θ1)}];
NΩ = − [Ecc {∂Φ(Y,X,D,Ω)/∂Ω}]−1 ;
µ1(d) = E[T {R(β0), X,Θ0, fX)|D = d];
µ4(d) = E{Φ(Y,X,D,Ω0)|D = d};
Λ(Yi, Xi, Di,Θ0) = MΩ(Θ0)NΩ(Ω0){Φ(Yi, Xi, Di,Ω0)− µ4(Di)}
−h2{Ri(β0), Xi, Di,Θ0}
+ [T {Ri(β0), Xi,Θ0, fX)− µ1(Di)] .
The asymptotic distribution of our estimator in the rare event case is given in
the following result, the proof of which is sketched in Appendix C.
Theorem 3 Let (Ω, β) = Θ, and let Θtrue denote its true value. Assume that
n1/n0 → c, where 0 < c < ∞. Also assume that Mβ is invertible. Under the rare
disease approximation that the distribution of X in the population is approximately
the same as the distribution of X among the controls, E{Λ(Y,X,D,Θtrue)|D} = 0
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and
n−1/2(β̂ − βtrue) = n−1/2
∑n
i=1Λ(Y,Xi, D,Θtrue) + op(1) (4.11)
→ Normal [0,Σ =∑1d=0(nd/n)cov{Λ(Y,X,D,Θtrue)|D = d}] .
An estimate of Σ can be obtained via the bootstrap or by substitution into the various
terms composing Λ(·) and then using its sample covariance matrix.
D. Simulation
We performed a small simulation study to assess the bias, coverage probability and
efficiency of our method with respect to linear regression only among the controls.
In our simulation study we generated X as Uniform(0,1), the regression model
for Y given X was taken as Y = β0 + β1X + ǫ, with β0 = β1 = 0. We considered
three distributions for ǫ. The conjectured model was Normal(0, σ2) with σ2 = 1.
The misspecified models were (a) Chisquared(7) centered and standardized to have
mean zero and variance one; and (b) centered and standardized Gamma(a, b), where
a = (0.4, 0.8, 1.4, 1.8) and b = 1.9. The logistic regression model has m(Y,X, θ1) =
θ11Y + θ12X , with θ11 = 0.25 and θ12 = 1. The value of θ0 = −3.70 was chosen so
that the rate of disease in the population for the normal case was π1 = 0.045. The
case-control study had n1 = 500 cases and n0 = 500 controls. We generated 1, 000
simulated data sets. We made the rare disease assumption, so that Ω = {κ, θ1 =
(θ11, θ12)}, and Ω was estimated by ordinary linear logistic regression of D on (Y,X).
For each simulated data set, the standard deviation of the β̂1 was estimated by 500
bootstrap samples. We use the rare disease assumption.
The results are displayed in Table 9, and our easily summarized. First, our
method is essentially unbiased. Second, it has actual coverage probabilities very close
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to the nominal level. Third, our method is much more efficient than using only the
controls, with mean squared error efficiencies ranging from 1.30 to 2.56.
Table 9. Simulation study for the estimation of β1
Mean S.D. Mean of C.P. of C.P. of MSE
Bias S.D. estimated S.D. 90% CI 95% CI Efficiency
Normal(0,1) 0.00 0.10 0.11 0.93 0.97 2.56
Chisquared(7) -0.01 0.12 0.12 0.90 0.95 1.78
Gamma(0.4,0.91) -0.02 0.13 0.14 0.91 0.96 1.30
Gamma(0.8,0.91) -0.01 0.13 0.13 0.91 0.96 1.42
Gamma(1.4,0.91) -0.01 0.12 0.12 0.89 0.95 1.51
Gamma(1.8,0.91) -0.01 0.12 0.12 0.91 0.95 1.62
E. An Empirical Example
We used our methodology to investigate two examples described by Chen, et al.
(2008). The basic purpose of the analysis is to show that in realistic settings, our
methodology leads to much more precise inference that regression using only the
controls.
1. Prostate Cancer
The first case-control study is one of prostate cancer. The sample includes 749
prostate cancer cases and 781 controls, selected from the screening arm of the Prostate,
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial at the National Can-
cer Institute (Gohagan, et al., 2000; Moslehi et al., 2006). In the notation of this
chapter, D is the prostate cancer case-control status and Y is the level of 1,25-
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dihydroxy-vitamin D. Let Z be age level categorized into four groups and hence with
three dummy variables. There are three single nucleotide polymorphisms (SNP) of
interest, with possible values 0, 1, 2: we call them SNP-1, SNP-2 and SNP-3. Then
X combines Z with each SNP, with a linear regression model, and we are interested
in the estimate of the SNP effect.
The results are given in Table 10. We see in this table that none of the coefficients
for the SNP are statistically significantly different from zero, which is one of the
expectations that Chen, et al. cite. Crucially, the 95% confidence intervals using our
method are much shorter than using the control data only, and when translated into
mean squared error efficiency, for the three SNP suggest gains in efficiency of 68%,
136% and 125%.
Table 10. Results of the VDR data example
Robust Regression
Lower Upper Lower Upper MSE
X Estimate CI CI Estimate CI CI Efficiency
SNP-1 0.015 -0.165 0.195 -0.029 -0.262 0.204 1.68
SNP-2 0.023 -0.047 0.093 0.039 -0.069 0.146 2.36
SNP-3 0.015 -0.062 0.092 -0.045 -0.161 0.070 2.25
2. Colorectal Adenoma
Chen, et al. also discuss a case-control study of colorectal adenoma, a precursor of
colorectal cancer. The study sample includes 628 prevalent advanced adenoma cases
and 635 gender-matched controls, also selected from the screening arm of the PLCO
Study. Here D is colorectal adenoma status and Y are various measures of smoking
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status, namely (a) years since stopping smoking, which we censor at 45; (b) Number
of packs smoked per day; and (c) pack years, i.e., packs per day times years smoked.
For the latter, as in Chen, at al., we subtracted 0.25 and censored at 100. Here Z is
age in years and gender, and X is Z combined with an indicator of the most common
diplotype against the rest. We are interested in estimating the effect of the most
common diplotype.
The results are given in Table 11. We see a statistically significantly protective of
the most common diplotype for the years since stopping smoking. Again,crucially, the
95% confidence intervals using our method are much shorter than using the control
data only, and when translated into mean squared error efficiency, for the three SNP
suggest gains in efficiency of 95%, 143% and 148%.
Table 11. Results of the NAT2 data example
Robust Regression
Lower Upper Lower Upper MSE
Y Estimate CI CI Estimate CI CI Efficiency
C S -3.501 -5.716 -1.318 -3.240 -6.307 -0.173 1.95
P Y -0.040 -0.199 0.120 0.210 -0.039 0.458 2.43
P D 0.063 -0.058 0.184 0.135 -0.047 0.317 2.48
F. Discussion
The study of the relationship among secondary variables in a case-control study is
of great practical interest, because large case-control studies now exist and especially
include predictors or phenotypes Y and demographic, environmental and genetic
factors. The homoscedastic regression model (4.1) is particularly important when
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the predictors or phenotypes are continuous random variables, as they are in our two
examples.
As we have noted, if one is willing to specify the distribution of the regression er-
rors in the population up to a parameter, then it is possible to estimate the parameter
β in model (4.1) in an efficient manner. However, we have shown that misspecification
of that parameter model will lead to inconsistent estimation of β: it is possible to
create skew distributions for the regression errors that result in bias when normality
is assumed.
Our approach is entirely different. While we specify a target regression error
distribution, we have shown that the estimation is robust to violation of that target
distribution, both theoretically and in a simulation study. In the rare disease case
that would be the reason for a case-control study in the first place, an alternative is
to simply use only the data for the controls. We have shown in simulations and in
our two data examples that such throwing away of 50% of the data leads to a highly
non-trivial loss of efficiency compared to our method.
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CHAPTER V
MODEL SELECTION IN JOINT MODELLING OF PAIRED FUNCTIONAL
DATA
Utilizing penalized B-splines, a new approach proposed by Zhou, et al. (2008) jointly
models a pair of sparsely observed functions through functional principal components.
In their approach, a stepwise addition and deletion procedure is employed to decide
upon the number of principal components (PCs) and crossvalidation is used to es-
timate penalty parameters. However the choice of the cutoff point in the stepwise
addition and deletion procedure is subjective and the crossvalidation computation is
very time consuming. In this project we propose to select the number of PCs and
estimate the penalty parameters with a modified version of the Akaike information
criterion (AIC) and two modified versions of the Bayesian information criterion (BIC).
Our methods are computationally fast and straightforward to implement. We illus-
trate our methods with simulations and the empirical data example used by Zhou, et
al. (2008).
A. Introduction
Recently, Zhou et al. (2008) proposed a modeling framework to study the relationship
between two sparsely observed functional variables. In this framework, the data for
each variable are viewed as smooth curves measured at discrete time-points plus ran-
dom errors. While the curves for each variable are summarized using a few important
principal components, the association of the two longitudinal variables is modelled
through the association of the principal component scores. Penalized splines are used
to model the mean curves and the principal component curves. The proposed model
can be cast into a mixed effects model framework for model fitting, prediction and
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inference, and the EM algorithm is used for computation.
There are two aspects of the methodology that need improvement. First, cross-
validation is used to estimate the penalty parameters, but this is computationally
expensive. Second, stepwise addition and deletion based upon the changes of the es-
timated PC score variances to decide on the numbers of PCs. However, this stepwise
method is ad hoc since setting up the thresholds for stoping addition and delection
is a subjective choice.
The goal of this study is to develop a computationally efficient procedure for
selecting the penalty parameters and an automatic procedure for selecting the num-
ber of principal components. We propose to apply widely used information criteria
such as the Akaike’s information criterion (AIC) (Akaike, 1973) and the Bayesian
information criterion (BIC) (Schwarz, 1978) in this functional data analysis problem.
The information criteria are applicable here because the modeling framework of Zhou
et al. (2008) is likelihood based. Use of the information criteria helps us avoid multi-
ple runs of the EM algorithm required by crossvalidation and thus can substantially
speed up the penalty parameter selection process. It also makes it automatic to select
the number of principal components.
While we focus on the modeling of paired curves in this project, we would like
to point out there is a literature on modeling single curves using functional principal
components. For example, James et al. (2000) and Rice and Wu (2001) used splines
to model the functional PCs. Peng and Paul (2009) used crossvalidation for selecting
the number of B-spline xobasis functions and developed a quadratic approximation
for fast computation. Yao et al. (2005) proposed to estimate the functional principal
components for sparse functional data through the eigen-decomposition of the covari-
ance kernel estimated using two-dimensional smoothing. They also proposed to use
AIC to select the number of principal components.
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The rest of the chapter is organized as follows. In Section B, we first briefly review
the modeling approach of Zhou et al. (2008), then define the degrees of freedom and
the information criteria for the smoothing parameter and model selection. In Section
C we apply our methods on simulated data sets and one real data example and
compare our results with that using crossvalidation.
B. Methodology
1. A Reduced Rank Model for Sparsely Observed Paired Curves
Let Yi(t) and Zi(t) denote the two measurements at time t for the i
th individual. The
joint model of Zhou et al. (2008) has the form
Yi(t) = µ(t) +
kα∑
j=1
fj(t)αij + ǫi(t) = µ(t) + f(t)
Tαi + ǫi(t),
Zi(t) = ν(t) +
kβ∑
j=1
gj(t)βij + ξi(t) = ν(t) + g(t)
Tβi + ξi(t).
(5.1)
where µ(t) and ν(t) are the mean curves, f = (f1, f2, .., fkα)
T and g = (g1, g2, .., gkβ)
T
are vectors of principal component curves, and ǫi(t) and ξi(t) are experimental errors.
The relationship between Yi(t) and Zi(t) is modeled through the correlation between
the principal component scores αi and βi. The αi’s, βi’s, ǫi’s and ξi’s are assumed
to have mean zero. The experimental errors ǫi(t) and ξi(t) are assumed uncorrelated
with constant variance σ2ǫ and σ
2
ξ , respectively. It is also assumed that the αi’s,
ǫi’s and ξi’s are mutually independent, as are the βi’s, ǫi’s and ξi’s. The principal
components are subject to the orthogonality constraints
∫
fjfl = δjl and
∫
gjgl = δjl,
with δkl being the Kronecker delta.
For identifiability purpose, the principal component scores αij , j = 1, . . . , kα, are
assumed independent with strictly decreasing variances, and similarly, the principal
53
component scores βij, j = 1, · · · , kβ, are also independent with strictly decreasing
variances. Denote the diagonal covariance matrices of αi and βi by Dα and Dβ,
respectively. Denote cov(αi, βi) = C. It is assumed that αi and βi are jointly normally
distribution so that αi
βi
 ∼ N{
0
0
 ,
Dα C
CT Dβ
}.
The observed data consist of Yi(t) and Zi(t) sampled at a finite number of obser-
vation times. For each individual i, let ti1, . . . , tini be the different time-points at which
measures are available. Based on the observed data, we estimate the unknown func-
tions using penalized splines where µ, ν, f and g are modeled as a member of the same
space of spline functions with dimension q. Let b(t) = {b1(t), . . . , bq(t)}T be an or-
thonomal basis of the spline space where the basis functions satisfy
∫
bj(t)bl(t) dt = δjl.
Let θµ and θν be q-dimensional vectors of spline coefficients such that
µ(t) = b(t)Tθµ, ν(t) = b(t)
Tθν . (5.2)
Let Θf and Θg be respectively q × kα and q × kβ matrices of spline coefficients such
that
f(t)T = b(t)TΘf , g(t)
T = b(t)TΘg. (5.3)
Write Yi = {Yi(ti1), .., Yi(tini)}T and similarly for Zi. Let Bi = {b(ti1), .., b(tini)}T.
The model for the observed data can be written as
Yi = Biθµ +BiΘfαi + ǫi,
Zi = Biθν +BiΘgβi + ξi,
βi = Λαi + ηi,
ǫi ∼ N(0, σ2ǫ Ini), ξi ∼ N(0, σ2ξIni), αi ∼ N(0, Dα), βi ∼ N(0, Dβ).
(5.4)
For identifiability of the model, we require that ΘTfΘf = I and Θ
T
gΘg = I, and the
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first nonzero element of each column of Θf and of Θg is positive.
Let L(Yi, Zi) denote the contribution to the likelihood from subject i. The joint
likelihood for the whole dataset is
∏n
i=1 L(Yi, Zi).Define matrixK =
∫
b′′(t){b′′(t)}Tdt.
The method of penalized likelihood minimizes the criterion
− 2
n∑
i=1
log{L(Yi, Zi; θµ, θν ,Θf ,Θg, Dα, Dβ, C)}
+ λµθ
T
µKθµ + λf
kα∑
j=1
θTfjKθfj + λνθTν Kθν + λg
kβ∑
j=1
θTgjKθgj ,
(5.5)
where θfj and θgj are, respectively, the j
th columns of Θf and Θg, and λµ, λν , λg, λg are
four penalty parameters. The EM algorithm is employed to minimize the penalized
likelihood criterion (5.5).
2. Selection of the Penalty Parameters
Because crossvalidation is computationally expensive in our context, as discussed in
Section 1, we propose to use information criteria such as AIC and BIC to select the
penalty parameters. Our proposal is motivated by existing results on asymptotic
equivalence of the CV criterion and the information criteria. In particular, Stone
(1977) and Shao (1997) showed that under some regularity conditions, the delete-one
subject CV criterion is asymptotically equivalent to AIC, while Shao (1997) showed
that the BIC and the delete-k subjects CV are asymptotically equivalent. Use of the
information criteria can substantially speed up the optimization program for selecting
the penalty parameters.
The AIC and BIC criteria are defined as
AIC = 2K − 2 log(L̂max), BIC = log(N)− 2 log(L̂max),
where K is the number of parameters in the model, N is the sample size, and L̂max
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is the maximized value of the likelihood function for the estimated model. Adding
penalties into the model fitting, it is not immediately clear how to count the number
of parameters. We propose to follow Section 3.13 of Ruppert, et al. (2003) and use the
effective degrees of freedom of the smoothers as the effective numbers of parameters.
For a giving penalty parameter λ, the effective degrees of freedom is defined as
df(λ) = trace
{( n∑
i=1
BTi Bi + λK
)−1 n∑
i=1
BTi Bi
}
,
Taking into account the effects of four penalty parameters, the total number of effec-
tive degrees of freedom for all four smoothing operations is
df(λµ, λν, λf , λg) = df(λµ) + df(λν) + kα × df(λf) + kβ × df(λg).
Then AIC in our context is defined as
AIC(λµ, λν , λf , λg) = 2 df(λµ, λν , λf , λg)− 2 log(L̂max).
We consider two versions of BIC where in the first version N is taken to be the
number of subjects Ns and in the second version N is taken to be the total number
of observations No. Specifically,
BICs(λµ, λν , λf , λg) = log(Ns) df(λµ, λν, λf , λg)− 2 log(L̂max),
BICo(λµ, λν , λf , λg) = log(No) df(λµ, λν , λf , λg)− 2 log(L̂max).
We select the penalty parameters by minmizing the above AIC, BICs or BICo criteria.
Note that to evaluate an information criterion for a fixed set of penalty param-
eters, the EM procedure only needs to be run once, compared with d times when
calculating the d-fold crossvalidation criterion. Therefore, roughly speaking, our in-
formation based procedure will take about 1/d of time compared with that using
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d-fold crossvalidation. Using information criteria also has other advantages. In par-
ticular, since the full data set is used in the estimation, the estimates are more stable
and in turn speeds up the EM procedure.
3. Selection of the Number of Important Principal Components
The information criteria defined above can also be used to select the number of
important principal components. To be specific, we first identify the ranges for kα
and kβ, which usually start from one and the largest values depend on the size of
the data. Next for a given pair of kα and kβ, estimate the smoothing parameters
following the procedure described in Section 2. Then record the AIC, BICs or BICo
values at the estimated smoothing parameters, denoted as AIC(kα, kβ), BICs(kα, kβ)
and BICo(kα, kβ). The selected numbers of principle components are (k
sel
α , k
sel
β ) =
argmin{(kα, kβ), AIC(kα, kβ)}, (kselα , kselβ ) = argmin{(kα, kβ), BICs(kα, kβ)}, or (kselα ,
kselβ ) = argmin{(kα, kβ), BICo(kα, kβ)}, respectively.
C. Application
1. Selection of the Smoothing Parameters in Simulation Studies
In this section we illustrate the proposed methods described in Section 2 and compare
the performance of our methods with that of the crossvalidation using simulated data
sets.
In each simulation run, we have n = 50 subjects. For simplicity of the presen-
tation, we sample each subject on 11 equally spaced time points from 0 to 1. Let
µ(t) = sin(2πt), ν(t) = sin(4πt). Let f1(t) = 1.4142cos(2πtij), f2(t) = 11.6508{(tij −
1/2)2 − cos(2πtij)/π2}, g1(t) = 1.4142cos(4πtij) and g2(t) = 9.0613{(xj − 1/2)2 −
cos(4πxj)/(4π
2)}. Note that f1(t) and f2(t) are orthonormal, as are g1(t) and g2(t).
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For subject i, i = 1, · · · , 50, at time tij = (j − 1)/10, j = 1, · · · , 10, we simulate Yij
and Zij from model (5.1) with σ
2
ǫ = 1, σ
2
ξ = 1 under the following three scenarios:
• kα = 1, kβ = 1, Dα = 4, Dβ = 2 and cov(αi, βi) =
√
2.
• kα = 2, kβ = 1, diag(Dα) = (4, 2), Dβ = 2, cov(αi1, βi) =
√
2 and cov(αi1, βi) =
0.
• kα = 2, kβ = 2, diag(Dα) = (4, 2), diag(Dβ) = (2, 1), cov(αi1, βi1) =
√
2 and
cov(αi2, βi2) = 0.5.
Under each scenario, 1,000 data sets were generated. As our focus here is on the
smoothing parameter selection, in our simulation studies the data were all fit using
the correct numbers of principal components. Ten-fold crossvalidation was used in
all comparisons.
The simulated data were fit following the procedure described in Section B. We
search over a four dimensional space for optimal smoothing parameters that minimize
crossvalidation, AIC, BICs and BICo. Optimization was realized in R using L-BFGS-
B by Byrd et. al. (1995). This optimizing method uses a limited-memory modification
of the BFGS quasi-Newton method and requires preset lower and/or upper bounds,
which were set at 0.1 and 105 respectively.
Table 12. Average ratios of the computing time using AIC, BICs and BICo to that
using 10-fold CV
CV/AIC CV/BICs CV/BICo
kα = 1, kβ = 1 12.0 8.7 6.9
kα = 2, kβ = 1 13.8 8.4 6.6
kα = 2, kβ = 2 11.7 10.8 8.7
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Table 12 gives the ratios of the computing time between using 10-fold crossvalida-
tion and the model selection criteria AIC, BICs and BICo. Under the three simulation
scenario, AIC is between 11.7 and 13.8 times faster than the 10-fold crossvalidation;
BICn is between 8.4 and 10.8 faster and BICo is between 6.6 and 8.7 times faster.
While the improvement in computing time is consistent for AIC it is most pronounced
in the scenario of kα = 2, kβ = 2.
Table 13. Average smoothing parameters and corresponding degrees of freedom se-
lected using 10-fold crossvalidation, AIC, BICs and BICo
λµ λν λf λg dfλµ dfλν dfλf dfλg
kα = 1 CV 40.4 10.3 43.2 5.2 8.3 9.3 8.3 10.1
kβ = 1 AIC 64.7 8.0 86.0 6.5 7.2 9.3 6.6 9.6
BICs 139.2 15.7 181.0 13.8 5.9 8.4 5.6 8.6
BICo 197.3 23.4 276.5 22.0 5.5 7.9 5.3 8.0
kα = 2 CV 43.9 8.9 54.6 6.6 8.2 9.5 7.5 10.0
kβ = 1 AIC 76.4 6.6 65.3 7.2 7.0 9.7 6.8 9.6
BICs 167.0 13.2 139.0 14.6 5.7 8.7 5.8 8.6
BICo 243.7 20.0 209.9 22.6 5.3 8.1 5.4 8.0
kα = 2 CV 39.1 9.7 52.0 14.6 8.4 9.6 7.7 9.0
kβ = 2 AIC 74.8 6.9 65.9 14.3 7.1 9.8 6.9 8.9
BICs 158.2 14.4 150.7 34.4 5.8 8.7 5.8 7.6
BICo 224.3 22.8 244.9 56.0 5.4 8.1 5.3 6.9
Table 13 shows the smoothing parameters chosen by different criteria and the
corresponding degrees of freedom defined in section 2. In general, BICo selected the
largest smoothing parameters while 10-fold crossvalidation selected the smallest.
In Table 14 we present the integrated mean squared errors of the mean functions
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and of the principal component functions, separably, as well as the average mean
squared errors of the variances of the principal component scores and of the variances
of measurement errors. With a few exceptions, our methods improve over that of the
10-fold crossvalidation. In most cases, BICs and BICo have smaller MSEs than AIC
in the estimation of the mean functions µ and ν, as well as σ2; AIC performs better
in estimating the principle component functions and the variances of the principle
component scores. All four methods have similar MSEs in estimating the covariance
matrix R of the principle component scores.
Table 14. Integrated mean squared errors
µ ν f g Dα Dβ R σ
2
ǫ σ
2
ξ
kα = 1 CV 0.08 0.05 0.01 0.02 0.06 0.03 0.25 0.0251 0.0046
kβ = 1 AIC 0.08 0.05 0.01 0.02 0.04 0.02 0.25 0.0015 0.0018
BICs 0.06 0.04 0.0064 0.02 0.04 0.04 0.25 0.0009 0.0012
BICo 0.05 0.03 0.0070 0.03 0.05 0.06 0.26 0.0007 0.0007
kα = 2 CV 0.12 0.05 0.05 0.03 0.03 0.03 0.26 0.0035 0.0070
kβ = 1 AIC 0.11 0.05 0.05 0.03 0.03 0.03 0.26 0.0030 0.0019
BICs 0.08 0.04 0.05 0.02 0.03 0.04 0.27 0.0016 0.0012
BICo 0.07 0.04 0.05 0.02 0.04 0.06 0.26 0.0012 0.0007
kα = 2 CV 0.12 0.10 0.06 0.12 0.03 0.01 0.16 0.0034 0.0038
kβ = 2 AIC 0.11 0.09 0.05 0.12 0.03 0.01 0.16 0.0028 0.0042
BICs 0.08 0.09 0.06 0.14 0.03 0.02 0.16 0.0014 0.0021
BICo 0.08 0.09 0.06 0.19 0.03 0.03 0.16 0.0011 0.0012
To summarize, the three proposed model selection criteria show great improve-
ment over using crossvalidation in model selection – all three methods dramatically
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reduce the computing time while improving the estimation precision. Among the
three criteria we proposed, AIC is fastest and BICo is slowest; in terms of estimating
the population mean curves and the measurement error variances, our results show
that BICo gives the smallest MSEs while AIC gives the largest MSEs; for the estima-
tion of the principle component functions and scores variances, AIC generally gives
the smallest MSEs and BICo gives the largest MSEs.
2. Selection of the Numbers of the Principle Components in Simulation Studies
We illustrate the selection of the numbers of the principle components with the pro-
posed criteria using simulation setup 3 in Section 1, where there are two principle
components for each variable. We generated 100 simulated data sets, applied the
model selection procedure using 10-fold crossvalidation suggested by Zhou, et. al.
(2008) as well as the procedure described in Section 3. In each simulation run, we set
the selection ranges of the numbers of the principle components from 1 to 3. There-
fore, there are 9 total possibilities for the pair (kα, kβ). Among the 100 simulations,
our proposed criteria picked the correct numbers of the PCs 100% of time while the
crossvalidation method was correct in 63% of time and selected (2, 1), (2, 3), (3, 1),
(3, 2) and (3, 3) the remaining 37% of the time. Our simulation results suggest the use
of one of the proposed criteria, gives not only faster, but also more accurate results.
3. Model Selection in the Rreal Data Example
Here we illustrate the proposed method using a data set from an AIDS clinical trial
ACTG 315 (Lederman et al. 1998) conducted by the AIDS Clinical Trials Group;
the same data was analyzed by Zhou, et al. (2008). In this clinical trial, forty-six
HIV-1 infected patients were treated with potent antiviral drugs (ritonavir, 3TC and
AZT). After initiation of the treatment on day 0, patients were followed for up to
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10 visits. Scheduled visit times common to all patients are 7, 14, 21, 28, 35, 42, 56,
70, 84 and 168 days. Since the patients did not follow exactly the scheduled times
and/or missed some visits, the actual visit times are irregularly spaced and different
for different patients. The visit time varies from day 0 to day 196. In the notation of
the joint model for paired functional data in Section 1, denote by Y the CD4+ cell
counts divided by 100 and by Z the base-10 logarithm of plasma hiv RNA copies.
To model the curves on the time interval [0, 196], cubic B-splines with 10 interior
knots were placed on scheduled visit times.
To fit this data, we need to estimate both the numbers of PCs and the smoothing
parameters. Due to the limited sample size, we restrict our choices of the numbers of
principle components (kα, kβ) to (1, 1), (1, 2), (2, 1), (2, 2) and (2, 3). We had difficulty
in computation with more than two PCs for CD4+ cell counts or more than three PCs
for the log viral load, largely because the variances of the PC scores were nearly zero.
Zhou, et al (2008) used 10-fold crossvalidation and chose one PC for CD4+ cell counts
and two PCs for the log viral load. Applying the procedure described in section 3, all
three criteria chose two principle components for both variables. As shown in Table
15, all three criteria scores have same patterns: the scores drop from (1, 1) to (2, 1),
(1, 2) and reach the lowest level at (2, 2). The biggest drop is from (2, 1) to (1, 2)
and the scores increase a little from (2, 2) to (2, 3). Based on the criteria scores, one
can either choose (2, 1) for the parsimony, as did in Zhou, et al. (2008), or choose
(2, 2) which we believe is the best model for this data. Compare our methods with
that of Zhou et al. (2008), in both models, the fitted values are similar; see Figure
2 for the mean curves and PC curves using kα = 1 and kβ = 2. On the other hand,
our methods are much faster: when one principal component for CD4+ cell counts
and two principal components for log viral load were used, AIC, BICs and BICo were
about 19 times faster; when two principal components for both CD4+ cell counts and
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log viral load were used, AIC, BICs and BICo were 10 - 12 times faster.
Table 15. AIC, BICs and BICo scores on AIDS data
(kα, kβ) AIC BICs BICo
(1, 1) -0.88 33.22 62.21
(2, 1) -11.82 29.13 62.26
(1, 2) -57.40 -28.79 5.02
(2, 2) -76.28 -45.34 -7.23
(2, 3) -75.11 -38.34 3.06
D. Discussion
We have shown how to select the smoothing parameters in joint model of paired sparse
functional data using novel versions of AIC and BIC. The methodology was described
for penalized spline mixed effects model and justified in the important paired sparse
functional data case. Numerically, we have found that AIC and BIC are very close
to being the same as 10-fold cross-validation in terms of model fits, while being much
faster computationally.
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Figure 2. Fitted mean curves and principal component curves using 10-fold crossvali-
dation, AIC, BICs and BICo for AIDS data.
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CHAPTER VI
PERMUTATION TEST FOR MICROARRAYS: COLONIC TUMORIGENESIS
PREDICTION IN THE EARLY STAGES OF DEVELOPMENT
In this study, we introduce a practical permutation test that uses cross-validated
genetic predictors to determine if the list of genes in question has “good” prediction
ability. We call it the cross-validated permutation test. It avoids overfitting by using
cross-validation to derive the genetic predictor and determines if the count of genes
that give “good” prediction could have been obtained by chance. This test is then
used to explore gene expression of colonic tissue and exfoliated colonocytes in the
fecal stream to discover similarities between the two, done at each of the three stages
of colonic tumorigenesis.
A. Introduction
1. Motivation for Genetic Influence on Colon Cancer
According to statistics compiled by the American Cancer Society in 2008 and 2009,
colon cancer is the third deadliest form of cancer in the U.S. among both men and
women. The prediction and eventual treatment of colon cancer at the early stages of
development is crucial for the population as a whole.
Moreover, the study of the development of cancer is not only of interest for the
benefit of public health as a whole, it is also an important topic for the successful
development of long term space missions, like traveling to Mars. In such long missions
humans would be exposed to prolonged doses of radiation which can potentially lead
to all types of cancerous tumors in a very short period of time. The attenuation
of these effects is therefore of great interest. To address these concerns our study
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design not only looks at cancerous tumor development as a result of exposure to
harmful chemical agents, it also considers the effects of radiation in tumorigenesis,
and specifically as it occurs in the colon.
In this work we study the prediction ability of genes to foretell colonic tumori-
genesis; however, to attack the problem of colon tumor development one must first
understand how the development occurs. Below we provide a brief description of the
stages of colonic tumor growth. The development of tumors in the colon happens
in 3 main stages: initiation, aberrant crypt foci (ACF) and finally tumor stage. At
the initiation stage the primary insult to the colon results in DNA damages. Con-
stant exposure to reactive oxygen species results in the damage to DNA, leading to
mutations. At the ACF or aberrant crypt foci stage, rogue colonic crypts begin to
form clusters or high multiplicity ACFs (HMACF) that signal the potential for tumor
development at these sites. Finally, the tumor stage is when actual tumors develop in
the colonic walls. As with HMACFs, tumors can be measured and counted to serve
as a phenotype that we can eventually predict.
It is well known that certain foods affect the development of cancer in the body
via anti-inflammatory mediators. More specifically n-3 polyunsaturated fatty acids,
found in fish oil, modulate the inflammatory process via genes such as interleukin-
1 β, see Kim et al. (2009). Hong et al. (2005) show that fish oil is protective
against oxidative DNA damage when compared against corn oil at the initiation
stage. Moreover, Hong et al. (1997) also show that fish oil is protective at each of
the three stages. Hence diet must be taken into account when studying the effects
certain genes have on the development of colonic cancer. Our study incorporates diet
by using a rat model where two different types of fiber (pectin and cellulose) and
two different types of oil (corn oil and fish oil) are employed. Tumor development is
induced by introducing both a chemical carcinogen, azoxymethane (AOM), as well
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as an environmental carcinogen, radiation.
In a compilation of all relevant studies that look at the contribution of genes on
gastric cancer in humans up to 2001, Gonzalez et al. (2002) found that interleukin-
1 β and NAT 1 variants are associated with increased gastric cancer. Hence the
expectation that certain genes may be able to predict colonic cancer is not without
merit.
Most genetic studies of colon cancer use gene expression from mucosal tissue ex-
tracted directly from the colon. This procedure is invasive and is not easily applicable
to human subjects. New ways to isolate mRNA from exfoliated colonocytes in the
fecal stream enable us to study the development of colonic cancer without invasive
procedures in both rats and humans, see Davidson et al. (1995) and Davidson et al.
(2003).
Our goal is to compare the prediction ability of genes to foretell colonic tu-
morigenesis at the ACF and tumor stages in both mucosal and fecal colonocytes via
microarray studies, albeit an indirect comparison but something that has never been
done until now.
This chapter is organized as follows: Section B gives a short description of the
data used to carry out the analysis, Section C introduces our permutation test and
gives results that provide specific gene lists that are able to predict tumor and non
tumor outcomes. Concluding remarks are in Section D.
B. Data
The data that will be used throughout this work are gene expression data generated
by the CodeLink System from GE. This platform is a gold standard for rat genome
studies and since our data come from rat models it is of course the method of choice.
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The normalization scheme used to make gene expression comparable between inde-
pendent arrays is performed by the GE system upon completion of the work, and
for most cases this scheme performs well. In our study, we are dealing with gene
expression derived from RNA found in mucosal tissue as well as in the fecal stream.
The standard normalization scheme works well on arrays from mucosal tissue; how-
ever, because of the normal degradation of RNA in the colon gene expression from
fecal matter is quite low and hence require a special normalization method. Liu et
al. (2005) studied this problem and developed a two-stage normalization scheme spe-
cially targeted to handle the problem of partially degraded RNA and it is one of the
methods we will use to normalize gene expression from the fecal stream.
In our aim to predict colonic tumorigenesis we will focus our efforts at both
the aberrant crypt foci or (ACF) and tumor stages of development. We will do our
prediction by using gene expression from RNA derived from both mucosal and fecal
samples. Mucosally derived microarrays are normalized via the standard method
while microarrays obtained from RNA in the fecal stream are normalized by both the
standard and two-stage methods. We will split our analysis into two parts, one where
all the genes in the microarray are considered as potential predictors and the other
where only a select number of genes, which will refer to as the rat colonic biomaker
list, is used. The genes in the rat colonic biomarker list are chosen because they are
known to be involved in the development of colon cancer.
The reason we are concentrating our efforts at ACF and tumor stages is simply
because the phenotypes are either inherently or can easily be dichotomized, and hence
prediction via well known classification methods can be readily accomplished. At the
tumor stage our outcomes are binary where a success indicates the existence of at
least one tumor in the colon and a failure means that no tumors where found in the
rat. At the ACF stage our binary outcomes where generated by dichotomizing the
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count of high multiplicity aberrant crypt foci (HMACF). If the count of HMACF was
greater than 4 we call that a success, which basically suggests a strong indication that
a tumor will appear. If the count was less than or equal to 4 then we deemed that
a failure. We label our successes at the ACF stage as tumor rats and our failures as
healthy rats.
At the ACF stage, there are fecal arrays for 15 healthy rats and 18 tumor rats
in the fecal arrays; while there are mucosal arrays, for 20 healthy rats and 13 tumor
rats. At the tumor stage, there are 39 healthy rats and 10 tumor rats with fecal array
data; while for the mucosal arrays, there are 61 healthy rats and 14 tumor rats.
Not only are we going to use gene expression to predict tumor outcomes, we will
also use additional factors of interest that influence the incidence of tumor develop-
ment. Recall that diet plays an important role in the development of colon cancer.
Both dietary fiber and lipid sources were manipulated in this study. The fiber sources
in the study were pectin and cellulose while the lipid sources were fish oil and corn
oil. Additional interest was placed on the mechanism by which carcinogenesis was
induced. In this study both a chemical carcinogen, azoxymethane or AOM, was em-
ployed as well as an environmental source: radiation. Overall the additional factors
to consider are: Diet and Radiation. Diet includes the four possible treatment com-
binations: fish oil with pectin (fishpect), fish oil with cellulose (fishcell), corn oil
with pectin (cornpect) and corn oil with cellulose (corncell). Radiation includes two
treatments: radiated or not.
In the next section we will introduce our permutation test and show how genes
are able to predict tumor outcomes and that their prediction ability surpasses that
of other covariates like diet and radiation.
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C. Analysis
In this section we are going to perform cross-validated permutation tests (CPT),
cross-validated within treatment permutation tests (CWPT) and diagonal linear dis-
criminant analysis (DLDA). We propose CPT to assess the prediction ability of the
genetic predictors in our data, and illustrate this method using the data from Khan
et al (2001). CWPT is proposed to assess the improvement that genetic predictors
have over clinical predictors in our data, such as diet and radiation. We illustrate
the use of the CWPT by applying it to the breast cancer data that is described in
Hofling and Tibshirani (2008). In both the cross-validated permutation test and the
cross-validated within treatment permutation test we classify the tumor and healthy
subjects using linear discriminant analysis (LDA) using one gene at a time. We use
DLDA to perform similar classification; however, we use DLDA on a larger set of
genes to produce a classifier rule for tumor and healthy subjects. Missing data were
imputed by nearest neighbor averaging (function pamr.knnimpute() in R).
1. Cross-validated Permutation Test (CPT)
The premise of our work revolves around the assumption that genes have the ability
to predict tumor outcome in colonic tissue whether it be at the aberrant crypt foci
stage or the final tumor stage. However it is difficult to discern how many genes play
a vital role when discriminating between tumor or healthy outcomes. Recent work
by Hua et al. (2009) shows that using more than 5 genes to build classifiers is not
only computationally daunting, it does not improve error rates. This finding justifies
a conservative approach and hence we will use at most one gene to build a classifier
and then use it to predict tumor outcomes. We will do this at the ACF stage and
then at the tumor stage.
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Our classifier scheme is Fisher’s LDA which assumes that each class in the data
possesses a multivariate normal distribution with a mean µk and a covariance matrix
Σk, where k is the class iterator. In our application our classes are binary and therefore
k will be either 1 = tumor, or 2 = no tumor. A main assumption of the LDA is that
the covariance is the same across class and therefore Σk = Σ for all k, where Σ is
some common covariance matrix. When applying the LDA one does not know the
mean and variance parameters ahead of time so those must be estimated. We use
leave-one-out cross validation to train, test and produce error rates from our classifier.
Using LDA, we produce a classifier that tries to predict tumor and non-tumor
outcomes with one gene as the predictor. From this predictor we obtain classification
errors in the form of false negative (FN) and false positive (FP) rates and do this
for each of the 30,000+ genes found in the CodeLink microarray. We obtain these
FN and FP values for each gene in arrays collected from the two samples: mucosal
and fecal. For mucosal array normalization is standard; however, since normalization
can be tricky for the arrays produced from fecal matter we produced classifiers for
gene expressions that were normalized by two-stage method and also by the standard
normalization generated by the GE system. All these steps were reproduced at both
the ACF and tumor stages of colonic tumorigenesis.
The expectation is that after all this we will find genes that predict tumor out-
comes. Low false positive and false negative rates are good indicators that a gene
is able to do this. But how do we know that set of genes having low error rates, as
defined by the procedure outlined above, did not occur by chance? We will test this
hypothesis by doing a permutation test.
In this analysis we count the number of genes at both ACF and tumor stage whose
false negative and false positive rates fall below an arbitrarily defined threshold b. In
our work, we took b = 0.2. After obtaining this count of genes which we will denote
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as N , we perform a permutation test to see if the count of genes, N, is significant. In
this permutation test, we permutate the class labels 200 times. For each permutation,
we then count the number of genes whose false negative and false positive rates fall
below b=0.2 in each time. Let B = 200, for b = 1, ..., B, let Nb be the count of genes
in the bth permutation. Then our p− value =∑Bb=1(Nb >= N)/B. We refer to this
as the cross-validated permutation test or (CPT). The cross-validation occurs when
we are building the classifier using the LDA.
We applied our cross-validated permutation test to the complete set of genes
found in the CodeLink arrays and on the shorter list of colonic biomarker genes. We
found that among all the genes in the complete list, 5 genes are statistically significant
with p − value = 0.015. These genes were found in the mucosal array at the ACF
stage and the gene IDs for these 5 genes are: GE1155319, GE1170229, GE1266696,
GE16725 and GE22209. We then performed CPT using one gene at a time plus diet
and radiation covariates as predictors and found one gene to be statistically significant
with p− value = 0.04. This gene was found in the two-stage normalized fecal array
at the tumor stage; the gene ID for this gene is GE21877, and it is also in the rat
colonic biomarker gene list.
We illustrate the ability of our method to detect genes of high predictive value by
applying it to the data from gene expression microarray experiments on small, round
blue-cell tumors (SRCTs), described in Khan et al (2001). There are four different
SRBCT tumor types: neuroblastoma (NB), rhabdomyosarcoma (RMS), non-Hodgkin
lymphoma (NHL), and the Ewing family of tumors (EWS). We found 87 genes are
statistically significant with p−value = 0. The counts of genes from 200 permutations
have mean 0 and standard deviation 0.
Using linear discriminant analysis with one gene as a predictor we were able to
find a short list of genes that can distinguish between individuals that have large
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numbers of ACF and those that do not. Using our cross-validated permutation test
we verified that the prediction ability of this set of genes did not occur at random,
and hence further research should aim towards discovering the function and role these
genes play in the development of colon cancer at the ACF stage. The inclusion of
radiation and diet as predictors in the CPT further revealed that interlukin 1β, or
GE21877, can distinguish between individuals that develop tumors and those that
do not. Further exploration revealed that elevated levels of this gene’s expression
correlates with the incidence of tumor, indicating that a high expression of this gene
could be a red flag if found in individuals at risk of colon cancer. However, only future
research can determine the usefulness of this gene as a prediction.
An interesting question arises from this analysis. How do the additional covari-
ates influence a genes ability to predict tumor outcomes? To answer this question we
introduce a new permutation test which also uses cross validation but now permutes
outcomes within a treatment class to asses the treatment’s influence on the classifier.
2. Cross-validated within Treatment Permutation Test (CWPT)
In this section we propose a cross-validated within treatment permutation test
(CWPT) to compare the prediction ability of genes to that of covariates like diet and
radiation. In this scenario we are testing the significance of the count of genes whose
joint false negative and false positive rates fall below that of the classifier formed by
only employing treatments as predictors. Again we are using LDA as the mode of
classification and the treatments used are covariates diet and radiation.
Define the false negative and false positive rates of a classifier that only includes
covariates as the predictors as FNc and FPc. These rates are constant for all the
genes. Let the false negative and false positive rates of classifiers that use both gene
expression and covariates as predictors be defined as FNcgi and FPcgi, where i is the
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gene iterator. Of course, FNcgi and FPcgi should not be greater than FNc and FPc
for gene i. Define Ti = I(FNcgi < (1 − a)FNc) × I(FPcgi < (1 − a)FPc), where
a = 0.2, 0.3, 0.4, 0.5, 0.6, 0.7. Here a indicates the improvement of the ith gene over
the covariate predictors. The larger the value of a the more improvement the gene
has over the covariates. If we define S =∑Ni=1 Ti, where N is the number of genes in
the entire gene list, then a reasonable hypothesis is:
H0: S has the same distribution as if the class labels were assigned at random
within each treatment;
HA: H0 false.
We propose a p-value from a permutation test to obtain the significance of im-
provement of gene predictors over the diet and radiation covariates. For b = 1, . . . , B,
we resample the subjects with replacement within treatment, and define the false
negative and false positive rates with covariates only as FN bc and FP
b
c ; then we
permutate the class labels within covariates, and define the false negative and false
positive rates with both diet and radiation covariates and gene expression for gene i
as FN bcgi and FP
b
cgi. Let Tbi = I(FN
b
cgi < (1− a)FN bc )× I(FP bcgi < (1− a)FP bc ) and
Sb =
∑N
i=1 Tbi, then our p-value is p = B
−1
∑B
b=1 I(Sb > S). We conclude that there
are S genes that improve classification significantly if the p-value for that S is less
than 0.10. We will refer to this as the cross-validated within treatment permutation
test or CWPT. We were liberal in our significance threshold of 0.10 since 0.05 was
too small to detect anything but one set of genes.
We performed the CWPT on the full list of genes from the two-stage normalized
fecal arrays, GE normalized fecal arrays and mucosal arrays at ACF and tumor stages.
Table 16 shows the number of genes that have false negative and false positive rates
that fall below that of the classifier using covariate predictors only and p-values of the
CWPT. In the two-stage normalized fecal array at ACF stage, there are 6980 genes
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that improve classification significantly when a = 0.2, with p-value p = 0.025. In the
GE normalized fecal array at the tumor stage, 415 and 50 genes improve classification
significantly when a = 0.4 and 0.5, with p-value p = 0.060 and 0.080 respectively.
Table 16. Permutation test within treatment for each gene in the entire gene list of
ACF and tumor stages.
ACF tumor
a n p n p
Fecal Arrays 0.2 6980(594) 0.025 1498(519) 0.484
Two-stage Normalized 0.3 393(176) 0.215 512(200) 0.469
0.4 166(93) 0.175 483(195) 0.328
0.5 15(12) 0.255 40(13) 0.359
0.6 2(2) 0.215 1(0) 0.422
0.7 1(0) 0.115 1(0) 0.125
Fecal Arrays 0.2 1652(1644) 0.260 2350(2296) 0.160
GE Normalized 0.3 385(385) 0.345 446(429) 0.245
0.4 143(143) 0.255 415(398) 0.060
0.5 19(19) 0.275 50(46) 0.080
0.6 1(0) 0.370 0(0) 1
0.7 0(0) 1 0(0) 1
Mucosal Arrays 0.2 689(687) 0.494 2(2) 0.760
0.3 205(204) 0.551 0(0) 1
0.4 44(44) 0.540 0(0) 1
0.5 44(44) 0.381 0(0) 1
0.6 2(2) 0.477 0(0) 1
0.7 0(0) 1 0(0) 1
Our cross-validated within treatment permutation test shows that there are great
number of genes that improve the classification of tumor phenotypes at both the
tumor and ACF stages of colonic tumorigenesis. Expression of 6980 genes at the
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ACF stage and that of 400+ genes at the tumor stage derived from fecal material
shows the most promise in having the ability to predict tumor outcomes above that
of treatment covariates: diet and radiation. This indicates that RNA harvested from
fecal material has the potential to predict tumor outcomes non-invasively and before
the actual development of the tumor.
The are a couple of drawbacks to this procedure. One is that now there are a very
large number of genes that we have to sort through to find only a handful that are of
true interest, and the other is that we used each gene as an independent predictor.
This is a reasonable assumption; however, using more than one gene to do prediction
might prove more powerful, if the selection process is appropriate. Inspired by these
observations we introduce a permutation test that uses more than one gene to predict
tumor outcomes.
3. Diagonal Linear Discriminant Analysis (DLDA)
As mentioned above, we now focus our methods so that multiple genes are used as
the predictors in the classifier machinery. Up to this point we have used LDA to the
classification, but because of the improved performance we will switch to the DLDA or
diagonal linear discriminant analysis, see Dudoit et al. (2002). As the name suggests
now the assumption on the covariance matrix of each class is equal but restricted to
a diagonal. The switch from LDA to DLDA is not major since up to this point we
have used only one gene as a predictor in the LDA, so in essence we have been doing
DLDA since the covariance matrix is of dimension 1× 1 and therefore diagonal.
As before we want to quantify the ability of genes to predict tumor outcomes
above and beyond the prediction that additional covariates provide. Our goal there-
fore, is not much different than what we presented in the previous section; however,
now we use DLDA and we use more than one gene as predictors.
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We performed a preliminary selection of genes based on the ratio of their between-
group to within-group sums of squares since lots of genes exhibit near-constant ex-
pression levels across samples. For gene j, the ratio is
BW (j) =
∑
i
∑
k I(yi = k)(x¯kj − x¯.j)2∑
i
∑
k I(yi = k)(xij − x¯kj)2
In the analysis, 15 and 25 genes with the largest BW ratio are selected at the ACF
stage and tumor stage, respectively. We selected the top 15 and 25 at the ACF and
tumor stages because they are approximately half the sample size found at each stage.
We performed DLDA on these selected genes, using leave-one-out cross validation to
build the classifier. We obtained the false negative and false positive rates using the
short list of genes; we obtained FN and FP rates using both the short gene list as well
as covariates and then performed our cross-validated within treatment permutation
test to assess the improvement of classification that genes demonstrate over covariates.
Define the false negative rate and false positive rate of the classifier that only
used the covariates as its predictors as FNc and FPc; and let the false negative rate
and false positive rate with both treatments and gene expression for all selected genes
be FNcg and FPcg. FNcg and FPcg should not be greater than FNc and FPc. A
reasonable hypothesis is:
H0 : FNc = FNcg and FPc = FPcg;
HA : FNcg < (1− a)FNc and FPcg < (1− a)FPc,
where a = 0, 0.1, 0.2. These hypotheses are reasonable because if the error rates of
the classifier which uses genes as predictors equal that of the classifier that did not
use genes as predictors, this means that the genes did not improve the classifier’s
ability to predict tumor outcomes. This is exactly what we want to find from these
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data.
Define T1 = (1 − a)FNc − FNcg, T2 = (1 − a)FPc − FPcg, and let G = (T 21 +
T 22 )I(T1 > 0, T2 > 0) be our test statistics. Then for b = 1, . . . , B, we resample the
animals with replacement within treatment, and define the false negative rate and
false positive rate with treatments only as FN bc and FP
b
c ; then we permutate the class
labels within treatment, and define the false negative rate and false positive rate with
both treatments and gene expression as FN bcg and FP
b
cg. Let Tb1 = (1−a)FN bc−FN bcg,
Tb2 = (1 − a)FP bc − FP bcg, and Gb = (T 21b + T 22b)I(T1b > 0, T2b > 0), then our p-value
is p = B−1
∑B
b=1 I(Gb >= G).
Table 17 shows the p-values for the entire gene list of normalized fecal arrays
at the ACF and tumor stages. At the tumor stage, the 25 selected genes in the GE
normalized fecal arrays improve the classification significantly over covariates when
a = 0 and 0.1. We did not find the genes in two-stage normalized fecal arrays and
mucosal arrays improve the classification significantly over covariates.
4. CWPT and DLDA on Breast Cancer Data
To show that our methods are comparable to others we apply our cross-validated
within treatment permutation tests to a published data set. We apply our CWPT
using one gene as the predictor and using a pre-selected set of genes. We will refer
to the one gene approach as the CWPT and the multigene approach simply as the
DLDA because it was used to do the classification when multiple genes we included.
We apply the CWPT and DLDA to the breast cancer data that is described in
Hofling and Tibshirani (2008) to illustrate our methods. This data consists of 4918
genes and 78 patients, in which 34 patients had poor prognosis and 44 patients had
a good prognosis. There are 6 covariates in this data set:
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Table 17. DLDA in the entire gene list of ACF and tumor stages.
ACF tumor
a p p
Fecal Arrays 0 0.065 1.000
Two-stage Normalized 0.1 1.000 1.000
0.2 1.000 1.000
Fecal Arrays 0 1.000 0.000
GE Normalized 0.1 1.000 0.000
0.2 1.000 1.000
Mucosal Arrays 0 1.000 1.000
0.1 1.000 1.000
0.2 1.000 1.000
• Tumor grade (good: 1,2; poor: 3)
• Estrogen receptor (ER) status (good: <= 10; poor: > 10)
• Progesterone receptor (PR) status (good: <= 10; poor: > 10)
• Tumor size (mm) (good: <= 20; poor: > 20)
• Patient age (yrs) (good: <= 40; poor: > 40)
• Angioinvasion (good: 0; poor: 1)
Since our analysis considers the two-way interactions of the covariates, we se-
lected the two covariates (ER and grade) that have the most significant main effects
in ANOVA.
After applying the CWPT we found 0 genes that have false negative rate and
false positive rate that fall below those when we use treatment covariates only. The
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false negative rate and false positive rate of the classifier with treatment covariates
as it only predictors are FNc = 0.500, FPc = 0.147.
We used the DLDA on these data, using 25 pre-selected genes, and found that
this list of genes did not improve the classification significantly, which is consistent
with the results from Hofling and Tibshirani (2008).
Our permutation tests are then shown to be comparable to pre-validation as
described by Hofling and Tibshirani (2008).
D. Conclusion
In this study, we developed cross-validated permutation test (CPT), cross-validated
within treatment permutation test (CWPT) and diagonal linear discriminant analysis
(DLDA) to assess the prediction ability of the genetic predictors in the gene expres-
sion data that are generated by CodeLink System from GE. From CPT, we found
5 genes in the mucosal array of ACF stage were statistically significant in terms of
predicting tumor outcome in colonic tissue; and 1 gene was significant in the two-
stage normalized array of tumor stage. By CWPT, we found hundreds to thousands
of genes improved classification significantly over covariates at both ACF and tumor
stages. From DLDA, the 25 selected genes in the GE normalized fecal arrays improve
the classification significantly over covariates at the tumor stage. The application on
SRCT data and breast cancer data gives similar results to those in Khan et al. (2001)
and Hofling and Tibshirani (2008).
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CHAPTER VII
CONCLUSION
In the first project we have shown how to test for a constant environmental effect
in general semiparametric regression models with interactions. The methodology
was described for kernel regression methods and justified in the important logistic
regression case. Numerically, we have found that regression spline approaches are
very close to being the same as kernel methods and much faster to compute, although
their theory remains an open question in this context.
The second project analyzed the relationship among secondary variables in a
case-control study, which is of great practical interest, because large case-control
studies now exist and especially include predictors or phenotypes Y and demographic,
environmental and genetic factors. As we have noted, the semiparametric efficient
approaches can be used to construct semiparametric score tests, but they suffer from
a lack of robustness to the assumed model for Y given X : it is possible to create skew
distributions for the regression errors that result in bias when normality is assumed.
Our approach is entirely different. The score statistic has mean zero under the null
hypothesis even the conjectured model is not correct, both theoretically and in a
simulation study. An alternative is to simply use only the data for the controls. We
have shown in simulations and in our two data examples that it suffer from lower
power compared to our method since it used only half of the data.
The third project took up the issue of estimation of a regression function when Y
given X follows a homoscedastic regression model in the secondary analysis of case-
control data. The homoscedastic regression model is particularly important when
the predictors or phenotypes are continuous random variables, as they are in our
two examples. As we have noted, if one is willing to specify the distribution of the
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regression errors in the population up to a parameter, then it is possible to estimate
the parameter β in an efficient manner. However, we have shown that misspecification
of that parameter model will lead to inconsistent estimation of β. Our approach is
entirely different. While we specify a target regression error distribution, we have
shown that the estimation is robust to violation of that target distribution, both
theoretically and in a simulation study. In the rare disease case that would be the
reason for a case-control study in the first place, an alternative is to simply use
only the data for the controls. We have shown in simulations and in our two data
examples that such throwing away of 50% of the data leads to a highly non-trivial
loss of efficiency compared to our method.
In the fourth project, we have shown how to select the smoothing parameters
in joint model of paired sparse functional data using novel versions of AIC and BIC.
The methodology was described for penalized spline mixed effects model and justified
in the important paired sparse functional data case. Numerically, we have found that
AIC and BIC are very close to being the same as 10-fold cross-validation in terms of
model fits, while being much faster computationally.
In the fifth project, we developed cross-validated permutation test (CPT), cross-
validated within treatment permutation test (CWPT) and diagonal linear discrimi-
nant analysis (DLDA) to assess the prediction ability of the genetic predictors in the
gene expression data that are generated by CodeLink System from GE. From CPT,
we found 5 genes in the mucosal array of ACF stage were statistically significant in
terms of predicting tumor outcome in colonic tissue; and 1 gene was significant in
the two-stage normalized array of tumor stage. By CWPT, we found hundreds to
thousands of genes improved classification significantly over covariates at both ACF
and tumor stages. From DLDA, the 25 selected genes in the GE normalized fecal
arrays improve the classification significantly over covariates at the tumor stage. The
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application on khan data and breast cancer data gives similar results to those in Khan
et al. (2001) and Hofling and Tibshirani (2008).
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APPENDIX A
TESTING FOR CONSTANT NONPARAMETRIC EFFECTS IN GENERAL
SEMIPARAMETRIC REGRESSION MODELS WITH INTERACTIONS
To illustrate the general result (2.7), we consider the partially linear logistic model
(2.2). However, it is clear from the expansions described in Section 3, which are quite
general, that the Wilks phenomenon result holds more generally.
Define W (γ) = 1 + γXTβ0.
1. Testing Theory
For the null model, we have that
pr(Y = 1|X,Z) = H(κ∗0 +XTβ∗0 + STη∗0)
independent of γ. Define θ(γ) so that κ∗0 + X
Tβ∗0 + S
Tη∗0 = X
Tβ0 + S
Tη0 + θ(γ) +
γXTβ0θ(γ). Then, under the null model,
pr(Y = 1|X,Z) = H{XTβ0 + STη0 +W (γ)θ(γ)}, (A.1)
while under the full model,
pr(Y = 1|X,Z) = H{XTβ0 + STη0 +W (γ)θ(Z, β0, η0, γ)}, (A.2)
and the null hypothesis is that
H0 : θ(z, β0, η0, γ) ≡ θ(γ). (A.3)
We have already described in Section 2 that we can treat (β∗0 , η
∗
0) and (β0, η0)
as if they were known. In this case, with the exception of the minor difference of
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the offset XTβ0 + S
Tη0 in (A.1) and (A.2), for any fixed γ the problem is exactly
the same as a special case of that studied by Fan, Zhang and Zhang (2001) in their
Theorem 10, which applies to generalized linear models. There are, however, huge
simplifications because the null hypothesis (A.3) takes a particularly simple form.
Let Kc(v) = K ∗K(v), the convolution function, and let Kch(v) = h−1Kc(v/h).
Define the volume of the support of Z to be V = E{1/fZ(Z)}, and also define
µn(h) = h
−1V{K(0)− (1/2) ∫ K2(t)dt} and σ2n(h) = 2µn(h)/rK , where
rK =
K(0)− (1/2) ∫ K2(t)dt∫ {K(t)− (1/2)Kc(t)}2dt.
Let Λn(γ) be the likelihood ratio test statistic. Then by Fan et al. (2001), under the
null hypothesis, independent of the value of γ, σ−1n (h){Λn(γ)−µn(h)} ⇒ Normal(0, 1).
This implies that the mean of rKΛn(γ) is rKµn(h) and the variance is 2µn(h)rK , as
one would have with a chi-squared random variable with rKµn(h) degrees of freedom,
see their Theorem 5 on page 165 and Theorem 10 on page 174.
Define
Ω(z0, γ) = fZ(z0)E[W
2(γ)H(1){XTβ0 + STη0 +W (γ)θ(Z, γ)}|Z = z0];
ǫ = Y −H{XTβ0 + STη0 +W (γ)θ(Z, γ)}.
Using Fan et al (2001) (see their page 191), which applies to generalized linear models
and allows heteroscedastic ǫi, we obtain
Λn(γ) = n
−1∑2
k=1
∑n
i=1Kh(Zk − Zi)ǫkǫiWi(γ)Wk(γ)/Ω(Zk, γ)
−(1/2)n−2∑2k=1∑ni=1∑nj=1H(1){XTk β0 + STk η0 +Wk(γ)θ(γ)}ǫiǫjWi(γ)
×Wj(γ)W 2k (γ){Ω(Zk, γ)}−2Kh(Zi − Zk)Kh(Zj − Zk)× {1 + op(1)}
= {Tn(γ)− Sn(γ)} × {1 + op(1)}.
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Also, modulo higher order terms, it follows that
Tn(γ) = h
−1K(0)E{1/fZ(Z)}+ n−1
n∑
k 6=i
Kh(Zk − Zi)ǫkǫiWk(γ)Wi(γ)/Ω(Zk, γ);
Sn(γ) = (1/2)h
−1E{1/fZ(Z)}
∫
K2(t)dt
+(2n)−1
n∑
k 6=i
Kch(Zi − Zk)ǫkǫiWk(γ)Wi(γ)/Ω(Zk, γ).
Make the definition
Un(γ) = n−1
n∑
k 6=i
{Kh(Zk − Zi)− (1/2)Kch(Zk − Zi)}ǫkǫiWk(γ)Wi(γ)/Ω(Zk, γ).
Then we have that
Λn(γ) = {µn(h) + Un(γ)}{1 + op(1)}.
It is obvious that these results are uniform in compact sets for γ. Since the terms
{1 + op(1)} are actually {1 + op(h−1/2)}, see Fan et al (2001), page 183, if D is such
a compact set, then uniformly in γ ∈ D, supγ∈D|h1/2{Λn(γ)− µn(h)} − h1/2Un(γ)| =
op(1). In section 2.b we show that h
1/2Un(γ), as a process in γ, converges to a Gaussian
process.
2. Weak Convergence of Un
To prove that the process h1/2Un(γ) converges to a Gaussian process in γ ∈ D,
we have to show that the finite dimensional distributions converge to normality, and
that the process is tight.
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Make the definitions
aii(γ) = 0;
aij(γ) = h
1/2{Kh(Zi − Zj)− (1/2)Kch(Zi − Zj)}Wi(γ)Wj(γ)/Ω(Zi, γ);
cij(γ) = n
−1{aij(γ) + aji(γ)}ǫiǫj ,
the latter two are defined when i 6= j. Then we have that
h1/2Un(γ) =
∑
1≤i<j≤n
cij(γ),
where once again we note that (ǫi, ǫj) are independent of γ under the null hypothesis.
We use Proposition 3.2 in de Jong (1987) to show that h1/2Un(γ) converges to a
Gaussian distribution for any fixed γ. Define
GI =
∑
1≤i<j≤n
E{cij(γ)4};
GII =
∑
1≤i<j<k≤n
[
E{c2ij(γ)c2ik(γ)}+ E{c2ji(γ)c2jk(γ)}+ E{c2ki(γ)c2kj(γ)}
]
;
GIV =
∑
1≤i<j<k<l≤n
[
E{cij(γ)cik(γ)clj(γ)clk(γ)}+ E{cij(γ)cil(γ)ckj(γ)ckl(γ)}
+E{cik(γ)cil(γ)cjk(γ)cjl(γ)}
]
;
To apply this proposition, we need to check the following conditions:
C1. h1/2Un(γ) is clean in the sense of de Jong (1987).
Using Definition 2.1 in de Jong (1987), we call h1/2Un(γ) is clean if the coditional
expectations of cij vanish, and this is obviously true since E(ǫ|X,S, Z) = 0.
C2. var{h1/2Un(γ)} converges to a finite quantity as n→∞.
C3. GI is of smaller order than var{h1/2Un(γ)}.
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C4. GII is of smaller order than var{h1/2Un(γ)}.
C5. GIV is of smaller order than var{h1/2Un(γ)}.
In what follows, we check conditions C2 - C5 as condition C1 follows directly
from the fact that E(ǫ|X,S, Z) = 0.
We use the following result:
Lemma 1 Let Zi and Zj are independent and identically distributed random vari-
ables with a strictly positive density and compact support and letK(·) be a symmetric
kernel. Define Km(c) to be the m− fold convolution of K(c). Then
E[K2h(Zi − Zj)Ω(Zj , γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}]
= h−1K2(0) E{1/f(Zi)}{1 +O(h)}
E[K22h(Zi − Zj)Ω(Zj, γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}]
= h−1K4(0) E{1/f(Zi)}{1 +O(h)}
E[K2h(Zi − Zj)Kh(Zi − Zj)Ω(Zj , γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}]
= h−1K3(0) E{1/f(Zi)}{1 +O(h)}
To check condition C2, first observe that
var{h1/2Un(γ)} =
∑
i<j
E{c2ij(γ)}
Then we derive
E{c2ij(γ)} = (n−2/4)E[{aij(γ) + aji(γ)}2ǫ2i ǫ2j ]
= (n−2/4)E[{a2ij(γ) + a2ji(γ) + 2aij(γ)aji(γ)}ǫ2i ǫ2j ]
= A1 + A2 + A3.
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Now we see that, using Lemma 1,
A1 = hn
−2E
(
[{Kh(Zi − Zj)− (1/2)Kch(Zi − Zj)}Wi(γ)Wj(γ)/Ω(Zi, γ)]2ǫ2i ǫ2j
)
= hn−2E
(
[{Kh(Zi − Zj)− (1/2)Kch(Zi − Zj)}]2Ω(Zj , γ)
× {fZ(Zj)fZ(Zi)Ω(Zi, γ)}−1
)
= n−2[K2(0)−K4(0) + (1/4)K4(0)]E{1/fZ(Z)}{1 + O(h)}.
Similarly,
A2 = n
−2[K2(0)−K3(0) + (1/4)K2(0)]E{1/fZ(Z)}{1 +O(h)};
A3 = n
−2[2K2(0)− 2K3(0) + (1/2)K4(0)]E{1/fZ(Z)}{1 +O(h)}.
Hence we have
lim
n→∞
var{h1/2Un(γ)} = lim
n→∞
∑
i<j
E{c2ij(γ)}
= [4K2(0)− 4K3(0) +K4(0)]E{1/fZ(Z)},
and hence condition C2 is satisfied.
Next, similar calculations as in Lemma 1 show that
E{a4ij(γ)ǫ4i ǫ4j} = O(h−1);
E{a2ij(γ)a2ji(γ)ǫ4i ǫ4j} = O(h−1),
and it follows that E{c4ij(γ)} = O(n−4h−1). Hence we have that GI = O(n−2h−1) =
o(1).
To check condition C4, we observe that,
E{a2ij(γ)a2ik(γ)ǫ4i ǫ2jǫ2k} = O(h−1);
E{aij(γ)aji(γ)aik(γ)aki(γ)ǫ4i ǫ2jǫ2k} = O(h−1),
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and similarly for other terms in the expansion of c2ij(γ)c
2
ik(γ). It follows that
E{c2ij(γ)c2ik(γ)} = O(n−4h−1). Hence we have that GII = O(n−1h−1) = o(1).
Finally, to check condition C5, we note that
E{aij(γ)ajk(γ)akℓ(γ)aℓi(γ)ǫ2i ǫ2jǫ2kǫ2ℓ} = O(h),
and similarly for other cross product terms, and thus implying
E{cij(γ)cjk(γ)ckℓ(γ)cℓi(γ)} = O(n−4h). Hence we get GIV = O(h) = o(1).
We have thus shown that conditions C1-C5 are satisfied and hence the proof is
complete.
We have to show that there exists ζ > 0, η > 1, such that, for any γ1 < γ < γ2,
hζE
{|Un(γ)− Un(γ1)|ζ |Un(γ)− Un(γ2)|ζ} ≤ |γ1 − γ2|η, (A.4)
see Billingsley (1968, page 128). We show below that (A.4) holds for ζ = 1.
Using the Cauchy-Schwarz inequality we observe
h2E2 {|Un(γ)− Un(γ1)||Un(γ)− Un(γ2)|} ≤ E
{
h1/2|Un(γ)− Un(γ1)|
}2
×E {h1/2|Un(γ)− Un(γ2)|}2 .
Recall that h1/2Un(γ) =
∑
1≤i<j≤n cij(γ). Let c
(1)
ij (γ) denote the first derivative of
cij(γ) with respect to γ and similarly for aij(γ). Now we see that
E
{
h1/2|Un(γ)− Un(γ1)|
}2
= E
[ ∑
1≤i<j≤n
{cij(γ)− cij(γ1)}
]2
= E
[ ∑
1≤i<j≤n
{cij(γ)− cij(γ1)}2
]
≤ (γ1 − γ2)2C,
where C = n2supγ,γ1∈[L,R]E[{cij(γ) − cij(γ1)}2]. Similar calculations can be done
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for E
{
h1/2|Un(γ)− Un(γ2)|
}2
, and hence hE {|Un(γ)− Un(γ1)||Un(γ)− Un(γ2)|} ≤
|γ1 − γ2|2C. The only thing remaining is to show that C is finite, which follows
immediately from condition C2.
Note that K(s) = K(−s) and since Z has a positive density function on a
compact support, we have E{1/fZ(Z)} =
∫
z
dz. Then
E{K2h(Zi − Zj)Ω(Zj , γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}}
= h−2
∫
K2{(zj − zi)/h}Ω(zj , γ)/{Ω(zi, γ)} dzi dzj
= h−1
∫
K2(t)Ω(zi + th, γ)/{Ω(zi, γ)} dzi dt
= h−1
∫
K2(t){Ω(zi, γ) +O(h)}/{Ω(zi, γ)} dZi dt
= h−1
∫
K2(t) dzi dt{1 +O(h)}
= h−1
∫
K2(t) dt E{1/f(Zi)}{1 +O(h)}
= h−1K2(0) E{1/f(Zi)}{1 +O(h)}.
Also,
E{K22h(Zi − Zj)Ω(Zj , γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}}
= h−2
∫
K22{(zj − zi)/h}Ω(zj , γ)/{Ω(zi, γ)} dzi dzj
= h−1
∫
K22 (t)Ω(zi + th, γ)/{Ω(zi, γ)} dzi dt
= h−1
∫
K22 (t){Ω(zi, γ) +O(h)}/{Ω(zi, γ)} dzi dt
= h−1
∫
K22 (t) dzi dt{1 +O(h)}
= h−1
∫
K22 (t) dt E{1/f(Zi)}{1 +O(h)}
= h−1K4(0) E{1/f(Zi)}{1 +O(h)}.
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Similarly, we derive
E{K2h(Zi − Zj)Kh(Zi − Zj)Ω(Zj , γ)/{fZ(Zj)fZ(Zi)Ω(Zi, γ)}}
= h−2
∫
K2{(zj − zi)/h}K{(zj − zi)/h}Ω(zj , γ)/{Ω(zi, γ)} dzi dzj
= h−1
∫
K2(t)K(t)Ω(zi + th, γ)/{Ω(zi, γ)} dzi dt
= h−1
∫
K2(t)K(t){Ω(zi, γ) +O(h)}/{Ω(zi, γ)} dzi dt
= h−1
∫
K2(t)K(t) dzi dt{1 +O(h)}
= h−1
∫
K2(t)K(t) dt E{1/f(Zi)}{1 +O(h)}
= h−1K3(0) E{1/f(Zi)}{1 +O(h)},
completing the proof.
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APPENDIX B
LOCALLY EFFICIENT SCORE TESTS FOR INDEPENDENCE IN THE
SECONDARY ANALYSIS OF CASE-CONTROL DATA
1. Robustness of the Efficient Score Test
Here we show that if the distribution of Y given X is misspecified, even under
the null hypothesis of independence between (Y,X), then the score statistic does not
in general have mean zero, and hence the score test is not robust.
We will use a result of Spinka, et al. (2005), who show that for any function
R(D, Y,X), under the null hypothesis
Ecc
{
n−1
∑n
i=1R(Di, Yi, Xi)
}
=
nπ0
n0
∫
fY (t)fX(x) (B.1)
×∑1d=0R(d, t, x)S(d, t, x,Ω)dtdx,
where Ecc(·) means expectation in the case-control sampling scheme, i.e., Ecc{G(D, Y,
X)} = n−1∑ni=1E{G(Di, Yi, Xi)|Di}.
Theorem 4 Let the true distribution of Y under the null hypothesis of independence
be fy,true(y), while the distribution of X is given as fx(x). Then Ecc{
∑n
i=1Kpar(Yi, Xi,
Ω)} = 0 does not hold in general, and indeed the expectation is given as
nπ0
n0
∫
fx(s)
{∫
L(t, s)fy,true(t)
∑1
d=0C(d, t, s,Ω)dt
}
ds
−nπ0
n0
∫
fx(s)
∫
fy,true(t)
∑1
d=0C(d, t, s,Ω)dt∫
fY (t)
∑1
d=0C(d, t, s,Ω)dt
×
{∫
L(u, s)fY (u)
∑1
d=0C(d, u, s,Ω)du
}
ds.
The proof is a simple consequence of (B.1), plus some detailed algebra.
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2. Proof of Theorem 1
Using (B.1), we see that
Ecc
{
n−1
∑n
i=1L(Yi, Xi, ζ)
}
=
nπ0
n0
∫
fY (t)fX(x) (B.2)
×∑1d=0L(t, x, ζ)S(d, t, x,Ω)dtdx.
Now note that
∑n
i=1
∑1
d=0
∫
S(d, Yi, x,Ω)pest(Yi)fX(x)dx
=
nπ0
n0
n−1
∑n
i=1
∫
fX(x)
∑1
d=0S(d, Yi, x,Ω)dx
×{
∫
fX(x)
∑1
d=0S(d, Yi, x,Ω)dx}−1
=
nπ0
n0
.
Hence the right hand side of (3.8) is exactly equal to
Λ =
n0
nπ0
∑n
i=1
∑1
d=0
∫
L(Yi, x, ζ)S(d, Yi, x,Ω)pest(Yi)fX(x)dx
= n−1
∑n
i=1
∑1
d=0
∫
L(Yi, x, ζ)S(d, Yi, x,Ω)fX(x)dx∫
fX(x)
∑1
d=0S(d, Yi, x,Ω)dx
= n−1
∑n
i=1
∑1
d=0
∫
L(Yi, x, ζ)fX(x)S(d, Yi, x,Ω)dx∑1
d=0
∫
fX(x)S(d, Yi, x,Ω)dx
= n−1
∑n
i=1U(Yi,Ω, ζ).
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Now apply (B.1), so that
Ecc(Λ) =
nπ0
n0
∫
fY (t)fX(x)
∑1
d=0U(t,Ω, ζ)S(d, t, x,Ω)dtdx
=
nπ0
n0
∫
fY (t)
∑1
d=0
∫
L(t, x, ζ)fX(x)S(d, t, x,Ω)dx∑1
d=0
∫
fX(x)S(d, t, x,Ω)dx
×
∫
fX(x)
∑1
d=0S(d, t, x,Ω)dxdt
=
nπ0
n0
∫
fY (t)
∫
fX(x)
∑1
d=0L(t, x, ζ)S(d, t, x,Ω)dx∫
fX(x)
∑1
d=0S(d, t, x,Ω)dx
×
∫
fX(x)
∑1
d=0S(d, t, x,Ω)dxdt
=
nπ0
n0
∫
fY (t)fX(x)
∑1
d=0L(t, x, ζ)S(d, t, x,Ω)dtdx. (B.3)
Since (B.2) and (B.3) are identical, we have thus shown that the test statistic (3.8)
numerically equals (3.10) and has mean zero under the hypothesis, as claimed.
Now we take up the question as to whether (3.10) has non-zero mean under the
alternative hypothesis. Under the alternative, Y and X and dependent, and we write
pr(X = x|Y ) = Q(x, y, κ), where Q(x, y, κ = 0) = fX(x). Define Salt(d, t, x,Ω, κ) the
same as S(d, t, x,Ω) except that fX(x) in the latter is replaced by Q(x, y, κ). As seen
in Chen, et al. (2008), for any function R(Y,X),
Ecc{n−1
∑n
i=1R(Yi, Xi)} =
nπ0
n0
∫
fY (t)fX(x)
∑1
d=0R(t, x)Salt(d, t, x,Ω, κ)dxdt.
Then we have that
Ecc{
∑n
i=1U(Yi,Ω, ζ)} =
nπ0
n0
∫
fY (t)fX(x)
∑1
d=0U(t,Ω, ζ)Salt(d, t, x,Ω, κ)dxdt
=
nπ0
n0
∫
fY (t)
∑1
d=0
∫
L(t, v, ζ)fX(v)S(d, t, v,Ω)dv∑1
d=0
∫
fX(u)S(d, t, u,Ω)du
×
∫
fX(x)
∑1
d=0Salt(d, t, x,Ω, κ)dxdt.
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Similarly,
Ecc{
∑n
i=1L(Yi, Xi, ζ)} =
nπ0
n0
∫
fY (t)fX(x)
∑1
d=0L(t, x, ζ)Salt(d, t, x,Ω, κ)dxdt.
Clearly, these expectations are generally different, and hence the test generally has
non-zero mean under alternatives.
3. Computation of (3.12)
Let erf(x) = 2Φ(
√
2x)− 1, where Φ(·) is the standard normal distribution func-
tion, and let φ(·) be the standard normal density function. Then ifA = ∫ ∑1d=0tSpar(d,
t, x,Ω, 0, ζ)dt and B =
∫ ∑1
d=0 Spar(d, t, x, Omega, 0, ζ)dt, we have that
A = β0 + (β0 + θ11σ
2)C;
B = 1 + C.
where C = exp(κ+ θ11β0 + θ12x+ θ
2
11σ
2/2). Both terms were computed using Math-
ematica, and checked numerically.
4. Asymptotic Distribution of V(Ω̂, ζ̂) in (3.11)
As in Theorem 2, n0/n1 → c, 0 < c < ∞. Let Θ = (Ω, ζ) and write Tn =
n1/2V(Ω̂, ζ̂). Define Gnum(y, x,Θ) = L(y, x, ζ)
∑1
d=0S(d, y, x,Ω) and Gden(y, x,Θ) =∑1
d=0S(d, y, x,Ω). Then
Tn = n
−1/2∑n
i=1
{
L(Yi, Xi, ζ̂)−
n−10
∑n
j=1(1−Dj)Gnum(Yi, Xj, Θ̂)
n−10
∑n
j=1(1−Dj)Gden(Yi, Xj, Θ̂)
}
.
DefineAnum(y,Θ) = E{Gnum(y,X,Θ)|D = 0} andAden(y,Θ) = E{Gden(y,X,Θ)|D =
0}. Define
M(y, x,Θ) = ∂
∂ΘT
{
L(y, x, ζ)− Anum(y,Θ)Aden(y,Θ)
}
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Define Ecc{M(Y,X,Θ)} = n−1
∑n
i=1E{M(Yi, Xi,Θ)|Di}. By simple calculations,
using our estimators of Θ as described in Section 3, we have that for some Θ0 and
some estimating function Φ(Y,X,D,Θ0),
n1/2(Θ̂−Θ0) = n−1/2
∑n
i=1Φ(Yi, Xi, Di) + op(1),
where Ecc{Φ(Y,X,D,Θ0)} =
∑n
i=1E{Φ(Yi, Xi, Di,Θ0)|Di} = 0. Make the definition
that µ5(d) = E{Φ(Y,X,D,Θ0)|D = d}, and since
∑n
i=1µr(Di) = 0, it follows that
Tn = n
−1/2
∑n
i=1
{
L(Yi, Xi, ζ0)−
n−10
∑n
j=1(1−Dj)Gnum(Yi, Xj,Θ0)
n−10
∑n
j=1(1−Dj)Gden(Yi, Xj ,Θ0)
}
+Ecc{M(Y,X,Θ0)}n−1/2
∑n
i=1{Φ(Yi, Xi, Di,Θ0)− µ5(Di)}+ op(1).
Define
Znum(Y,Θ0) = n
−1/2
0
∑n
j=1(1−Dj) {Gnum(Yi, Xj,Θ0)−Anum(Y,Θ0)} ;
Zden(Y,Θ0) = n
−1/2
0
∑n
j=1(1−Dj) {Gden(Yi, Xj,Θ0)−Aden(Y,Θ0)} .
Since by assumption n0/n1 → c, 0 < c <∞, we have that Znum{R(β0),Θ0} = Op(1)
and Zden{R(β0),Θ0} = Op(1). Thus,
n−10
∑n
j=1(1−Dj)Gnum(Y,Xj,Θ0)
n−10
∑n
j=1(1−Dj)Gden(Y,Xj,Θ0)
− Anum(Y,Θ0)Aden(Y,Θ0)
=
Anum(Y,Θ0) + n−1/20 Znum(Y,Θ0)
Aden(Y,Θ0) + n−1/20 Zden(Y,Θ0)
− Anum(Y,Θ0)Aden(Y,Θ0)
=
n
−1/2
0 Znum(Y,Θ0)
Aden(Y,Θ0) −
Anum(Y,Θ0)
A2den(Y,Θ0)
n
−1/2
0 Zden(Y,Θ0) + op(n
−1/2
0 ).
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Under regulatory conditions it follows that
Tn = n
−1/2
∑n
i=1 {L(Yi, Xi,Θ0)− U(Yi,Θ0)}
+n−1/2
∑n
i=1
{
U(Yi,Θ0)− Anum(Yi,Θ0)Aden(Yi,Θ0)
}
−n−10 n−1/2
∑n
i=1
∑n
j=1(1−Dj)
Gnum(Yi, Xj,Θ0)−Anum(Yi,Θ0)
Aden(Yi,Θ0)
+n−10 n
−1/2∑n
i=1
∑n
j=1
Anum(Yi,Θ0)
A2den(Yi,Θ0)
(1−Dj){Gden(Yi, Xj,Θ0)−Aden(Yi,Θ0)}
+Ecc{M(Y,X,Θ0)}n−1/2
∑n
i=1Φ(Yi, Xi, Di) + op(1)
= D1 +D2 +D3 +D4 +D5 + op(1).
We now proceed to analyze these terms in turn. By the rare disease assumption,
D2 = 0 since U(Yi,Θ0) ≈ Anum(Yi,Θ0)/Aden(Yi,Θ0). We know from Theorem 1 that
if µ1(d) = E{L(Y,X,Θ0)− U(Y,Θ0)|D = d}, then
∑n
i=1µ1i(Θ0) = 0, this latter sum
being the expectation in the case control sampling scheme. Hence
D1 +D2 +D5 = n−1/2
∑n
i=1{L(Yi, Xi, ζ0)− U(Yi,Θ0)− µ1(Di)}
+n−1/2
∑n
i=1Ecc{M(Y,X,Θ0)}{Φ(Yi, Xi, Di)− µ5(Di)}
= n−1/2
∑n
i=1 K(Yi, Xi, Di,Θ0),
say, where E{K(Y,X,D,Θ0)|D} = 0.
Similarly, note that
0 = µ3(d, y) = E
{
(1−D)Gnum(y,X,Θ0)−Anum(y,Θ0)Aden(y,Θ0) |D = d
}
0 = µ4(d, y) = E
[
(1−D)Anum(y,Θ0){Gden(y,X,Θ0)−Aden(y,Θ0)}A2den(y,Θ0)
|D = d
]
.
Let c∗ = n/n0. Hence,
D3 +D4 = c∗n−3/2
∑n
i=1
∑n
j=1W (Yi, Xj, Dj ,Θ0),
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where
W (Yi, Xj, Dj,Θ0) = −(1−Dj)Gnum(Yi, Xj ,Θ0)−Anum(Yi,Θ0)Aden(Yi,Θ0)
+(1−Dj)Anum(Yi,Θ0){Gden(Yi, Xj,Θ0)−Aden(Yi,Θ0)}A2den(Yi,Θ0)
.
Notice that W (y, x, d = 1,Θ0) = 0 and E{W (y,X, d = 0,Θ0)|D = 0} = 0. With-
out loss of generality, we can make the first n0 observations be controls, and the
last n − n0 observations be the cases. Define Z˜i = (Yi, Xi, Di), Q1(Z˜i, Z˜j,Θ0) =
W (Yi, Xj , Dj,Θ0) + W (Yj, Xi, Di,Θ0), Q2(z˜,Θ0) = E{W (Y, x, d,Θ0)|D = 1} and
h1(z˜,Θ0) = E{Q1(z˜, Z˜,Θ0)|D = 0}. Then
D3 +D4 = c∗n−3/2
∑n
i=1
∑n0
j=1W (Yi, Xj, Dj,Θ0)
= c∗n
−3/2∑n0
i=1
∑n0
j=1W (Yi, Xj, Dj,Θ0)
+c∗n
−3/2∑n
i0+1
∑n0
j=1W (Yi, Xj, Dj,Θ0)
= c∗n
−3/2∑n0
i=1
∑n0
j<iQ1(Z˜i, Z˜j,Θ0)
+c∗n1n
−3/2
∑n0
j=1n
−1
1
∑n
i0+1
W (Yi, Xj, Dj ,Θ0) + op(1).
An easy calculation shows that
var
[
n−3/2
∑n0
j=1
∑n
i0+1
W (Yi, Xj, Dj,Θ0)− n1n−3/2
∑n0
i=1Q2(Z˜i,Θ0)
]
→ 0.
Hence we have shown that
D3 +D4 = c∗(n0/n)3/2n−3/20
∑n0
i=1
∑n0
j<iQ1(Z˜i, Z˜j,Θ0)
+c∗n1n
−3/2∑n0
i=1Q2(Z˜i,Θ0) + op(1).
Except for the factor c∗(n0/n)
3/2, the first term above is a classical symmetric U-
statistic of order two applied to independent and identically distributed observations,
since by convention the first n0 observations are the controls. It then follows from
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standard U-statistic results that
D3 +D4 = c∗(n0/n)3/2n−1/20
∑n0
i=1h1(0, Z˜i,Θ0) + c∗n1n
−3/2
∑n0
i=1Q2(Z˜i,Θ0) + op(1)
= c∗(n0/n)n
−1/2
∑n
i=1(1−Di)h1(Di, Z˜i,Θ0)
+c∗(n1/n)n
−1/2
∑n
i=1(1−Di)Q2(Z˜i,Θ0) + op(1)
= n−1/2
∑n
i=1h2{Ri(β0), Xi, Di,Θ0}+ op(1),
say, where of course E[h2{R(β0), X,D,Θ0}|D] = 0. Define Λ(Y,X,D,Θ0) = K(Y,X,
D,Θ0) + h2(Y,X,D,Θ0). Because of the way we have set things up, Ecc{Λ(Y,X,D,
Θ0)} = 0 and the normalized test statistic satisfies
Tn = n
−1/2∑n
i=1Λ(Yi, Xi, Di,Θ0) + op(1)→ Normal(0,Σ);
Σ = = covcc(Y,X,D,Θ0) =
∑1
d=0(nd/n)cov{Λ(Y,X,D,Θ0)|D = d}.
In principle, all the terms in Λ(·,Θ0) can be estimated, and a method of moments
covariance matrix can constructed separately for both the cases and the controls in
order to estimate Σ.
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APPENDIX C
LOCALLY EFFICIENT ESTIMATION FOR HOMOSCEDASTIC REGRESSION
IN THE SECONDARY ANALYSIS OF CASE-CONTROL DATA
1. Unbiasedness of the Estimation Function (4.9)
Since this is a case-control sampling scheme, all expectations are conditional on
(D1, ..., Dn). Let Ecc denote the expectation under the case-control sampling scheme
and G an arbitrary function. Then, with (βtrue,Ωtrue) the true parameter, β an
arbitrary value, τ(x, β, βtrue) = µ(x, βtrue)− µ(x, β), and with R(β) = Y − µ(X, β),
Ecc [G{R(β), X}] =
∑1
d=0(nd/n)E[G{Y − µ(X, β), X}|D = d].
In order to derive the conditional density given the disease state we use the fact
that we assume a logistic model, P (D = 1|Y,X) = H{θ0 +m(Y,X, θ1)}, with H(x)
is the logistic distribution function, for which H{θ0 + m(Y,X, θ1)} = [1 − H{θ0 +
m(Y,X, θ1)}] exp{θ0+m(Y,X, θ1)}. Now write fY X(·) as the joint density/mass func-
tion of (Y,X) in the population. Then, with θ0 and θ1 denoting the true parameters,
πd = P (D = d)
=
∫
H{θ0 +m(y, x, θ1)}d[1−H{θ0 +m(y, x, θ1)}]1−dfY X(y, x) dy dx
=
∫
[1−H{θ0 +m(y, x, θ1)}] exp[d{θ0 +m(y, x, θ1)}]fY X(y, x) dy dx.
It then follows that the density/mass function of (Y,X) given D
fY X|D=d(y, x) =
exp[d{θ0 +m(y, x, θ1)}]fY X(y, x)
[1 + exp{θ0 +m(y, x, θ1)}]πd .
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If we make the rare disease assumption, this becomes exp[d{θ0+m(y, x, θ1)}]fY X(y, x)
×π−1d . Recall that κ = θ0 + log(n1/n0)− log(π/π0). The above expectation can now
be computed as
Ecc [G{R(β), X}]
=
∑1
d=0
nd
nπd
∫
G{y − µ(x, β), x} exp[d{θ0 +m(y, x, θ1)}]fY X(y, x) dy dx
=
n0
nπ0
∫ ∑1
d=0G{y − µ(x, β), x}
nd/n0
πd/π0
exp[d{θ0 +m(y, x, θ1)}]fY X(y, x) dy dx
=
n0
nπ0
∫
G(r, x)[1 + exp[κ+m{r + µ(x, β), x, θ1}]fY X{r + µ(x, β), x} dr dx.
We now note that the joint density/mass function of (Y,X) in the population is
fY X(y, x) = fǫ{y − αtrue − µ(x, βtrue)}fX(x). Hence, fY X{r + µ(x, β), x} = fǫ{r −
αtrue − τ(x, β, βtrue)}fX(x). Thus,
Ecc [G{R(β), X}]
=
n0
nπ0
∫
G(r, x)[1 + exp[κ +m{r + µ(x, βtrue)− τ(x, β, βtrue), x, θ1}]
×fǫ{r − αtrue − τ(x, β, βtrue)}fX(x) dr dx
=
n0
nπ0
∫
G{r + τ(x, β, βtrue), x}[1 + exp[κ +m{r + µ(x, βtrue), x, θ1}]
×fǫ(r − αtrue)fX(x) dr dx.
Now, since K(r, x, βtrue,Ωtrue) = 1 + exp[κ +m{r + µ(x, βtrue), x, θ1}], we have that
Ecc [G{R(β), X}] (C.1)
=
n0
nπ0
∫
fǫ(r − αtrue)fX(x)K(r, x, βtrue,Ωtrue)G{r + τ(x, β, βtrue), x}drdx.
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It follows from (C.1) that
nπ0
n0
Ecc{Qn(αtrue, β,Ωtrue)}
= n1/2
∫
fǫ(r − αtrue)fX(x)K(r, x, βtrue,Ωtrue)
×
[
L{r + τ(x, β, βtrue), x, α(β,Ωtrue), β}
−
∫
L{r + τ(x, β, βtrue), v, α(β,Ωtrue), β}K{r + τ(x, β, βtrue), v, β,Ωtrue}∫ K{r + τ(x, β, βtrue), s, β,Ωtrue}fX(s)ds
×fX(v)dvdxdr
]
.
If β = βtrue, since τ(x, βtrue) = 0, it follows directly that Ecc{Qn(αtrue, βtrue,Ωtrue)}
= 0, and hence that Qn(β,Ω) is an unbiased estimating equation. If β 6= βtrue, then
in general we will have 0 6= Ecc{Qn(αtrue, β,Ωtrue)}.
2. A Technical Lemma
The following Lemma is used in our analysis, including for the intercept. Refer
to the definitions before the statement of Theorem 3.
Lemma 1 Under regulatory conditions, as (n0, n1) → ∞ such that n0/n1 → c, with
0 < c <∞,
Hn(β,Θ) = n−1/2
∑n
i=1h2{Ri(β), Xi, Di,Θ}+ op(1), (C.2)
where E[h2{R(β), X,D,Θ}|D] = 0.
Sketch of Proof: Define
Znum{R(β),Θ} = n−1/20
∑n
j=1(1−Dj) [Gnum{R(β), Xj,Θ)−Anum{R(β),Θ}] ;
Zden{R(β),Θ} = n−1/20
∑n
j=1(1−Dj) [Gden{R(β), Xj,Θ} − Aden{R(β),Θ}] .
Since by assumption n0/n1 → c, 0 < c < ∞, we have that Znum{R(β),Θ} = Op(1)
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and Zden{R(β),Θ} = Op(1). Thus, by a Taylor series expansion
n−10
∑n
j=1(1−Dj)Gnum{R(β), Xj}
n−10
∑n
j=1(1−Dj)Gden{R(β), Xj}
− Anum{R(β),Θ}Aden{R(β),Θ}
=
Anum{R(β),Θ}+ n−1/20 Znum{R(β),Θ}
Aden{R(β),Θ}+ n−1/20 Zden{R(β),Θ}
− Anum{R(β),Θ}Aden{R(β),Θ}
=
n
−1/2
0 Znum{R(β),Θ}
Aden{R(β),Θ} −
Anum{R(β),Θ}
A2den{R(β),Θ}
n
−1/2
0 Zden{R(β),Θ}+ op(n−1/20 ).
Thus,
Hn(β,Θ) = n−10 n−1/2
∑n
i=1
∑n
j=1(1−Dj)
Gnum{Ri(β), Xj,Θ} − Anum{Ri(β),Θ}
Aden{Ri(β),Θ}
−n−10 n−1/2
∑n
i=1
∑n
j=1
Anum{Ri(β),Θ}
A2den{Ri(β),Θ}
×(1 −Dj) [Gden{Ri(β), Xj,Θ} − Aden{Ri(β),Θ}] + op(1)
= D1 +D2 + op(1).
By definition, E(D1|D1, ..., Dn) = E(D2|D1, ..., Dn) = 0. Let c∗ = n/n0. By the
definition of Gnum, etc.,
D1 +D2 = c∗n−3/2
∑n
i=1
∑n
j=1W{Ri(β), Xj, Dj,Θ},
Notice that W (r, x, d = 1,Θ) = 0. Without loss of generality, we can make the first
n0 observations be the controls, and the last n− n0 observations be the cases. Then
D1 +D2 = c∗n−3/2
∑n
i=1
∑n0
j=1W{Ri(β), Xj, Dj,Θ}
= c∗n
−3/2
∑n0
i=1
∑n0
j=1W{Ri(β), Xj, Dj,Θ}
+c∗n
−3/2
∑n
i0+1
∑n0
j=1W{Ri(β), Xj, Dj,Θ}
= c∗n
−3/2∑n0
i=1
∑n0
j<iQ1{Z˜i(β), Z˜j(β),Θ)
+c∗n1n
−3/2∑n0
j=1n
−1
1
∑n
i0+1
W{Ri(β), Xj, Dj,Θ}+ op(1).
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An easy calculation shows that
var
[
n−3/2
∑n0
j=1
∑n
i0+1
W{Ri(β), Xj, Dj ,Θ} − n1n−3/2
∑n0
i=1Q2{Z˜i(β), β,Θ}
]
→ 0.
Hence we have shown that
D1 +D2 = c∗(n0/n)3/2n−3/20
∑n0
i=1
∑n0
j<iQ1{Z˜i(β), Z˜j(β), β,Θ}
+c∗n1n
−3/2
∑n0
i=1Q2{Z˜i(β), β,Θ}+ op(1).
Except for the factor c∗(n0/n)
3/2, the first term above is a classical symmetric U-
statistic of order two applied to independent and identically distributed observations,
since by convention the first n0 observations are the controls. It then follows from
standard U-statistic results that
D1 +D2 = c∗(n0/n)3/2n−1/20
∑n0
i=1h1{0, Z˜i(β), β,Θ}
+c∗n1n
−3/2∑n0
i=1Q2{Z˜i(β), β,Θ}+ op(1)
= c∗(n0/n)n
−1/2∑n
i=1(1−Di)h1{Di, Z˜i(β), β,Θ}
+c∗(n1/n)n
−1/2
∑n
i=1(1−Di)Q2{Z˜i(β), β,Θ}+ op(1)
= n−1/2
∑n
i=1h2{Ri(β), Xi, Di,Θ}+ op(1).
This completes the sketch of Lemma 1.
3. Sketch of the Asymptotic Theory for β̂
Under the rare disease approximation, the estimate is consistent for βtrue, and
α(βtrue,Ωtrue) = αtrue. Define MΩ, T {R(β), X,Θ, fX,cont}, and Mβ as in Section 6.
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Define
J {R(β), X, β,Ω) = µβ(X, β)−
∫
µβ(x, β)K{R(β), x, β,Ω}fX,cont(x)dx∫ K{R(β), x, β,Ω}fX,cont(x)dx ;
c1n(β,Ω) = n
−1
∑n
i=1J {Ri(β), Xi, β,Ω);
c1(β,Ω) = Ecc[J {R(β), X, β,Ω)}.
We are solving 0 = Q̂n,est(β̂, Ω̂). By a Taylor series expansion,
0 = Q̂n,est(βtrue,Ωtrue) +
∂
∂βT
n−1/2Q̂n,est(βtrue,Ωtrue)n
1/2(β̂ − βtrue)
+
∂
∂ΩT
n−1/2Q̂n,est(βtrue,Ωtrue)n
1/2(Ω̂− Ωtrue) + op(1).
However, it is clear that for any (β,Ω), n−1/2Q̂n,est(β,Ω) = Ecc[T {R(β), X,Θ, fX,cont}]
+op(1). Hence it follows that
0 = Q̂n,est(βtrue,Ωtrue) +Mβn1/2(β̂ − βtrue) +MΩn1/2(Ω̂− Ωtrue) + op(1).
Because of its form,
Q̂n,est(βtrue,Ωtrue) = Q̂n(αtrue, βtrue,Ωtrue)
+c1(βtrue,Ωtrue)n
1/2{α̂(βtrue,Ωtrue)− α(βtrue,Ωtrue)}+ op(1).
However, under the rare disease approximation, when we replace fcont(·) by fX(·) in
the definition of J (·), by the same argument as in Section 1, c1(βtrue,Ωtrue) = 0. In
addition, using the same tools as in Lemma 1, n1/2{α̂(βtrue,Ωtrue)−α(βtrue,Ωtrue)} =
Op(1). We have thus shown that
n1/2(β̂ − βtrue) = −Mβ
{
Q̂n(αtrue, βtrue,Ωtrue) +MΩn1/2(Ω̂− Ωtrue)
}
+ op(1). (C.3)
Remember that K(r, x,Θ) = 1+ exp[κ+m{r+µ(x, β), x,Ω}]. Define Φ(y, x, d,Ω) =
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{1, mΩ(y, x, θ1)}T[D −H{κ+m(y, x, θ1)}] and
NΩ = − [Ecc {∂Φ(Y,X,D,Ω)/∂Ω}]−1 .
Because Ω = (κ, θ1) is estimated by ordinary logistic regression, it follows from stan-
dard theory that
n−1/2(Ω̂− Ωtrue) = n−1/2
∑n
i=1NΩΦ(Yi, Xi, Di,Ωtrue).
We thus have from (C.3) that
n1/2(β̂ − βtrue) = −Mβ
{
Q̂n(αtrue, βtrue,Ωtrue)
+MΩn−1/2
∑n
i=1NΩΦ(Yi, Xi, Di,Ωtrue)
}
+ op(1). (C.4)
We are now in a position to apply Lemma 1 to Q̂n(αtrue, βtrue,Ωtrue). In or-
der to apply Lemma 1, we define Gnum(r, x,Θ) = L{r, x, α(β,Ω), β}K(r, x,Θ) and
Gden(r, x,Θ) = K(r, x,Θ). Invoking Lemma 1, it follows that
Q̂n(βtrue,Θtrue) = n
−1/2
∑n
i=1T {Ri(βtrue), Xi,Θtrue, fX,cont)
−n−1/2∑ni=1h2{Ri(βtrue), Xi, Di,Θtrue}+ op(1).
We now make the rare disease assumption, and thus set fX(x) = fX,cont(x), and we
have
Q̂n(βtrue,Θtrue) = n
−1/2∑n
i=1T {Ri(βtrue), Xi,Θtrue, fX)
−n−1/2∑ni=1h2{Ri(βtrue), Xi, Di,Θtrue}+ op(1).
We have shown in Section 1 that the first term has mean zero. That is, if
µ1(d) = E[T {R(βtrue), X,Θtrue, fX)|D = d],
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then
∑n
i=1µ1(Di) = 0. Hence we have shown that
Q̂n(βtrue,Θtrue) = n
−1/2
∑n
i=1 [T {Ri(βtrue), Xi,Θtrue, fX)− µ1(Di)]
−n−1/2∑ni=1h2{Ri(βtrue), Xi, Di,Θtrue}+ op(1).
Remember that E[h2{R(βtrue), X,D,Θtrue}|D] = 0. Now let µ4(d) = E{Φ(Y,X,D,
Ωtrue)|D = d}, and because of the unbiasedness of the estimating equation for logistic
regression,
∑n
i=1µ4(Di) = 0. Summarizing, we have shown that
n−1/2(β̂ − βtrue) = −M−1β (Θtrue)n−1/2
∑n
i=1Λ(Yi, Xi, Di,Θtrue) + op(1);
Λ(Yi, Xi, Di,Θtrue) = MΩ(Θtrue)NΩ(Ωtrue){Φ(Yi, Xi, Di,Ωtrue)− µ4(Di)}
−h2{Ri(βtrue), Xi, Di,Θtrue}
+ [T {Ri(βtrue), Xi,Θtrue, fX)− µ1(Di)] ;
0 = E[Λ(Y,X,D,Θtrue)|D],
as claimed.
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